ABSTRACT

Cushing’s syndrome results from chronic exposure to excessive circulating levels of glucocorticoids. Cushing’s disease is the most common cause of endogenous hypercortisolism. The recommended screening tests include the 1mg overnight dexamethasone suppression test, late-night salivary cortisol, and 24-hour urinary free cortisol (at least two 24-hour collections). If the initial test is positive on 2 occasions the patient should be evaluated by an endocrinologist for further assessment. An elevated midnight serum cortisol and no suppression of cortisol during a low-dose dexamethasone suppression test will confirm endogenous hypercortisolemia. Plasma 09:00h ACTH measurement guides imaging and further investigations. If ACTH is elevated/inappropriately normal, MRI scanning of the pituitary should be performed, but if ACTH is suppressed imaging of the adrenals should follow. The corticotrophin releasing hormone (CRH) test helps distinguishing pituitary from ectopic ACTH-dependent Cushing's syndrome, while bilateral petrosal sinus sampling remains the gold standard test and should be considered, if available, with the exception of the presence of a macroadenoma. Transsphenoidal surgery is the first line treatment for Cushing’s disease, followed by radiotherapy as a second-line option. Adrenalectomy is the first-choice treatment for adrenal ACTH-independent Cushing’s syndrome and resection of the ACTH source should be performed for the ectopic ACTH-dependent Cushing’s syndrome, where possible. Steroidogenesis inhibitors remain the most effective medical agents and are useful when surgery or the effects of radiotherapy are awaited or are unsuccessful. For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG.

INTRODUCTION

Cushing’s syndrome results from chronic exposure to excessive circulating levels of glucocorticoids. It is now more than one hundred years since Harvey Cushing reported the classical clinical syndrome that bears his name. Even now, its investigation and management can vex the most experienced endocrinologist. It may be difficult to miss the diagnosis in its most florid form but, given the high prevalence of many of its non-specific symptoms such as obesity, muscle weakness, and depression, clinicians are now required to consider the diagnosis in its earlier manifestations. The plethora of investigations often needed for the diagnosis and differential diagnosis has grown over the intervening century, and require careful interpretation. In its severe form and when untreated, the metabolic upset of Cushing's syndrome is associated with a high mortality. However, more subtle excesses of cortisol may also have significant effects on glycemic control and blood pressure, and may therefore be an important cause of morbidity. Treatment is often complex and may require all the modalities of surgery, radiotherapy and medical management.

PATHOPHYSIOLOGY, ETIOLOGY, AND EPIDEMIOLOGY OF CUSHING’S SYNDROME

In normal physiology the final product of the hypothalamo-pituitary-adrenal (HPA) axis is the glucocorticoid cortisol, secreted from the zona fasciculata of the adrenal gland under the stimulus of adrenocorticotropin (ACTH) from the pituitary gland. ACTH is secreted in response to corticotrophin releasing hormone (CRH) and vasopressin from the hypothalamus. Cortisol exerts negative feedback control on both CRH and vasopressin in the hypothalamus, and ACTH in the pituitary. In normal individuals, cortisol is secreted in a circadian rhythm; levels fall during the day from a peak at 07.00h-08.00h to a nadir at around midnight: they then begin to rise again at 02.00h.

It is the loss of this circadian rhythm, together with loss of the normal feedback mechanism of the hypothalamo-pituitary-adrenal (HPA) axis, which results in chronic exposure to excessive circulating cortisol levels and that gives rise to the clinical state of endogenous Cushing's syndrome (1, 2). Any of the numerous synthetic steroids that have glucocorticoid activity, if administered in excessive quantities, can give rise to exogenous Cushing's syndrome. This is the commonest cause of Cushing's syndrome seen in general clinical practice, usually due to treatment for chronic conditions such as asthma or rheumatological disease.

The etiology of Cushing's syndrome can broadly be divided into two categories, ACTH-dependent and ACTH-independent (Table 1).

ACTH-dependent forms are characterized by excessive ACTH production, which stimulates all three layers of adrenal cortex and results in bilateral adrenocortical hyperplasia and hypertrophy of adrenal gland. This results in increased weight of the adrenals, which often show micronodular or sometimes macronodular changes. Circulating glucocorticoids are increased and often, to a lesser extent, are accompanied by a rise in serum androgens.

ACTH-independent forms constitute a heterogeneous group characterized by low levels of plasma ACTH, either because of adrenal glucocorticoid hypersecretion or secondary to the exogenous administration of glucocorticoids. Except for adrenal adenomas, which usually secrete only glucocorticoids, among the other endogenous adrenal entities there is usually also a rise in androgens and sometimes steroid precursors. The microscopic and macroscopic appearance of non-affected adrenal tissue mainly depends on the etiology of the disorder.

CLINICAL MANIFESTATIONS OF CUSHING’S SYNDROME

The clinical manifestations in Cushing’s syndrome result from a chronic exposure to excess glucocorticoids and show a wide spectrum of abnormalities, from mild, subclinical disease to florid manifestations.

The classical impression of the disease in its most obvious form, as the association of gross obesity of the trunk with wasting of the limbs, facial rounding and plethora, hirsutism with frontal balding, muscle weakness, spontaneous bruising, vertebral fractures, hypertension and diabetes mellitus, is less commonly seen nowadays (Table 3) (46-48). More frequently, the clinical diagnosis may be equivocal because many symptoms common in Cushing's syndrome, including lethargy, depression, obesity, hypertension, hirsutism, and menstrual irregularity, are also very common in the general population. Therefore, it is useful to have an investigation strategy exploring the more specific features considering the diagnosis, most helpfully relating to the catabolic features of glucocorticoid excess. It is very helpful to notice presence of several signs and symptoms, accompanied by a progressive course. Sequential photographs of the patient over many years can be extremely helpful in demonstrating progression to a Cushingoid state.

The clinical manifestations are usually determined by the duration and amplitude of glucocorticoid exposure, but in some aggressive courses of ectopic ACTH secretion, such as small cell carcinoma, symptoms of hypercortisolism are hard to detect because of the predominant malignant signs and symptoms such as weight loss and anorexia.

The type of steroid excess is determined by the underlying condition. Adrenal adenomas generally secrete glucocorticoids, but in case of an ACTH-dependent disease or a carcinoma additional hyperandrogenism is common.

It is important to observe that combinations of Cushingoid features very much depend on the natural course of its underlying cause.

Patients with the ectopic ACTH syndrome usually present with severe and rapidly developing metabolic signs, most prominently anorexia, myopathy and glucose intolerance. Because of severe hypercortisolemia and additional mineralocorticoid effect, hypokalemic alkalosis is found with peripheral oedema on clinical examination. The combination of rapid clinical deterioration, hyperpigmentation, hypokalemic alkalosis and clinical signs of mineralocorticoid excess should be indicative for suspicion of a small cell lung carcinoma secreting ACTH. In contrast, patients with ACTH-producing bronchial carcinoids, because of the long duration of hypercortisolemia before clinical presentation, tend to develop all of the typical Cushingoid features, complicating its differentiation from Cushing’s disease.

Patients with adrenal carcinomas have a rapid onset of symptoms, and may complain of abdominal pain accompanied with a palpable tumor mass. In addition to hypercortisolism, they often secrete mineralocorticoids and androgens, therefore distinguishing them from benign adenomas which usually secrete cortisol alone (49).

In 10 percent of patients with adrenal incidentalomas, “subclinical” Cushing’s syndrome (better called ‘autonomous cortisol secretion’) can be found; this is characterized by mild hypercortisolism without very obvious clinical manifestations of Cushing’s syndrome (50).

Unlike men, where the main source of androgens is the testes, in women a substantial proportion of circulating androgens are adrenal in origin, such that the signs and symptoms of adrenal hyperandrogenism are readily diagnosed by symptoms of hirsutism and acne, and signs of virilization.

Obesity and weight gain are among the most common signs in Cushing’s syndrome. The distribution of fat can be useful, as typically in Cushing's syndrome there is increased visceral adiposity giving rise to truncal obesity, fat deposition in the cheeks and temporal fossae ("moon face"), dorsocervical area ("buffalo hump"), and supraclavicular fat pads (46, 51). Rarely, fat deposition in the epidural space can be manifest as a neurological deficit (52), while retrorbital deposition is noticeable as exophthalmos (53). In children, more generalized weight gain associated with growth retardation should highlight the possibility of the diagnosis (2). Other signs that are more discriminatory are proximal myopathy, wide purple striae, osteoporosis, thin skin and easy bruising. Based on the study of 369 individuals with obesity, or weight in the overweight range, there were no reported cases of Cushing’s syndrome (54). Therefore, screening patients with generalized obesity and no specific features of Cushing’s syndrome is generally not recommended.

Myopathy of the proximal muscles of the lower limb and shoulder results from a catabolic glucocorticoid effect. When assessing for myopathy it is useful to ask questions about function typically affected by proximal muscle weakness, such as climbing stairs or getting up from a chair. Formal testing can be of leg extension whilst sitting, or rising unaided from a squatting position. Muscle weakness can be exacerbated by hypokalemia, as a result of concomitant mineralocorticoid activity; it is uncommon in pseudo-Cushing’s states (1).

Osteoporosis occurs in approximately 50% of adult patients (55, 56) and can be assessed by formal bone densitometry, or from a history of fractures, typically vertebral due to the preferential loss of trabecular bone induced by glucocorticoids. Glucocorticoids inhibit osteoblast function (57). Vertebral compression fractures lead to height loss. Rib fractures are often painless, with typical radiographic appearance of exuberant callus. Also, osteonecrosis (aseptic necrosis) of the femoral head has been described, usually in relation to iatrogenic Cushing’s syndrome following chronic high dose glucocorticoid therapy (58). After successful treatment of the cause, bone density improves to a large extent (59, 60).

There are many changes in the skin and subcutaneous tissue, which are rarely seen in the general population, suggesting the possibility of Cushing’s syndrome (1, 46). The result of hypercortisolemia is thinning of the skin, which is best tested over the dorsum of the hand, visible as “cigarette paper” (Liddle’s sign), but it is helpful to consider the age and gender of the patient as natural atrophy increases with age and female gender. In addition, skin thickness may be preserved in women with hyperandrogenemia related to Cushing's syndrome. The classic plethora (facial redness) is not only a consequence of skin thinning but also of a loss of a facial subcutaneous fat. Because subcutaneous fat and elastic tissue is also diminished, patients suffer easy bruising, which often can be misinterpreted as senile purpura or even a coagulation disorder. Purple-colored "violaceous" striae greater than 1 cm in diameter are almost pathognomonic of Cushing's syndrome (Figure 1). Typically seen on the abdomen, they can also occur in other areas, such as the thighs, breasts and arms. Narrow and colored striae are more commonly present, and should be differentiated from the typical healed pearl striae seen most commonly post-partum.

Figure 1.

The wide purple striae on the abdominal wall due to Cushing’s syndrome (permission of the patient obtained).

Increased fine non-pigmented vellus hair on the upper cheeks or forehead may be seen in Cushing’s syndrome, as well as more typical terminal hair hirsutism on the face and body, reflecting increased androgens. Cutaneous fungal infections as truncal tinea versicolor and onychomycosis are often found.

Skin hyperpigmentation is much more common in ectopic Cushing’s syndrome (most often from small cell lung carcinoma) than Cushing’s disease. It is also associated with the rapid onset of profound weakness, often with little or no weight gain, and an absence of a gross Cushingoid appearance. However, as noted above, other forms of the ectopic ACTH syndrome, particularly associated with neuroendocrine tumors, may be clinically indistinguishable from patients with other forms of hypercortisolism (61).

Severe hirsutism and virilization strongly suggest an adrenal carcinoma (62).

Hypercortisolism may suppress other pituitary hormones. In both men and women, hypogonadotrophic hypogonadism is common and correlates with the degree of hypercortisolemia (63). Glucocorticoids inhibit gonadotrophin–releasing hormone pulsatility and the release of luteinizing (LH) and follicle-stimulating hormone (FSH). Women experience menstrual irregularity, while both sexes have decreased libido. Gonadal dysfunction is reversible after correction of the hypercortisolemia (64). In addition, the coexistence of polycystic ovarian syndrome in Cushing’s syndrome is common (65). There is reduced GH secretion during sleep and blunted GH responses to dynamic stimulation tests (66). Thyrotropin-releasing hormone and thyroid-stimulating hormone release has been shown to be disturbed, and in particular the nocturnal surge of thyroid-stimulating hormone is lost (67). This may not have a significant effect on free thyroid hormone levels during active hypercortisolemia, but there is a significantly increased prevalence of autoimmune thyroid disease in patients successfully treated for Cushing’s syndrome, and it is therefore important to follow them with serial thyroid function tests (68, 69).

Hypokalemic metabolic alkalosis is related to the degree of hypercortisolemia and represents a mineralocorticoid action of cortisol at the renal tubule due to saturation of the enzyme 11β-hydroxysteroid dehydrogenase type 2, which inactivates cortisol to cortisone and allows selective binding of aldosterone to the mineralocorticoid receptor (70). In terms of hypersaturation, cortisol can now access the mineralocorticoid receptor and act as a mineralocorticoid. It occurs when urine free cortisol excretion is greater than about 4100 nmol per day (71). Therefore, although a more common feature of ectopic ACTH secretion, it may also occur in approximately 10% of patients with Cushing’s disease.

Cushing’s syndrome is characterized by insulin resistance and hyperinsulinemia. Glucose intolerance is evident in 20%-30%, and overt diabetes mellitus in 30%-40% of patients (72-75). Glucocorticoids stimulate glycogen deposition, promote gluconeogenesis, inhibit glucose uptake in peripheral tissues, activate lipolysis and have a permissive effect on the counter-regulatory hormones, glucagon and catecholamines. It has been suggested that 2-3% of overweight, poorly-controlled patients with diabetes may have occult Cushing’s syndrome (76, 77). However, in the absence of clinical suspicion the percentage is lower (78, 79), and therefore it is probably not justified to screen for Cushing’s in poorly-controlled diabetic patients unless other suggestive features are present (80). Hyperglycemia becomes easier to control after treatment (81).

There is an increase in total cholesterol and triglyceride levels, and a variable effect on high-density lipoprotein (HDL) (82). These changes are multifactorial, including cortisol effects on increased hepatic synthesis of very low density lipoprotein (VLDL), lipolysis, and free fatty acid metabolism (83).

The major cause of mortality in Cushing’s disease are cardiovascular events, and patients exhibit direct markers of accelerated cardiovascular disease, including increased carotid artery intima-media thickness and atherosclerotic plaques (84) as well as hypertension, glucose intolerance, overt diabetes mellitus, dyslipidemia and visceral obesity. Overall, hypertension is common in patients with Cushing’s syndrome (74). Severe hypertension with additional hypokalemia is more prevalent in ectopic Cushing’s syndrome, usually best controlled with spironolactone or related drug (85). Cardiovascular risk markers continue to be present long after cure of the hypercortisolemia (86) and the cardiovascular risk remains increased (87, 88). Sympathetic autonomic function is also abnormal in patients with Cushing's syndrome (89), and the ECG abnormalities of a prolonged QTc dispersion and left ventricular hypertrophy have been identified as characteristic features in patients with Cushing's disease (90).

Hypercortisolemia increases clotting factors including factor VIII, fibrinogen, and von Willebrand factor, and reduces fibrinolytic activity. This along with other risk factors such as obesity, surgery and invasive investigative procedures, results in a significantly increased risk of thrombotic events in patients with Cushing's syndrome (91). Rates of thromboembolic events, either postoperatively or unrelated to surgery, are higher in patients with Cushing’s syndrome than the estimated incidence in an age and sex matched control population (92). Venous thromboembolism (VTE) has been reported in 20% of patients with Cushing’s syndrome who did not receive thromboprophylaxis at a mean follow-up of 6-9 years (93). In contrast, VTE occurred in only 6% of patients who received a therapeutic dose of unfractionated heparin at least for 2 weeks after any surgery. The hypercoagulable state may persist even up to12 months of Cushing’s syndrome remission and some experts recommend thromboprophylaxis from 24 hours following surgery; however, there is no clear evidence substantiating the duration of prophylaxis (94).

Ophthalmic complications include glaucoma and exophthalmos due to retroorbital fat deposition (95). Cataract is rare, mostly a complication of diabetes.

Psychiatric symptoms such as insomnia, depression, anxiety, easy irritability, paranoid episodes, and attempted suicide or panic attacks are present in more than half of patients having any cause of Cushing’s syndrome (96, 97). Cognitive defects as learning, cognition and impairment of short-term memory may be prominent (98, 99). These changes are not always reversible with treatment.

In patients with Cushing's syndrome there is a greater frequency of infections because of inhibition of immune function by glucocorticoids by decreasing the number of CD4 cells, NK cells and inhibition in cytokine synthesis (100), with predominant effects on cell-mediated immunity (Th1 responses). The most common are bacterial infections, and special attention should be pointed to the possibility of opportunistic pathogens, especially in cases of severe hypercortisolism (101).

Some cases of ACTH-dependent Cushing's syndrome occur in a periodic or cyclical form, with intermittent and variable cortisol secretion, the symptoms and signs waxing and waning according to the active periods of the disease. These patients can cause particular diagnostic difficulty, as it is imperative that the diagnostic tests are performed in the presence of hypercortisolemia to allow accurate interpretation. Patients may 'cycle in' or 'cycle out' over periods of months or years; if at presentation they are eucortisolemic, they will need regular re-evaluation usually with urinary free cortisol or late-night salivary cortisol to allow full investigation at the appropriate time. Cyclicity can in fact occur with all causes of Cushing’s syndrome (102).

BIOCHEMICAL CONFIRMATION OF CUSHING’S SYNDROME

As stated above, there are many clinical features in various combinations in Cushing’s syndrome, but a small number of pathognomonic ones, such as myopathy, skin thinning and bruising, usually suggest the need for biochemical investigation. The basis for establishing the diagnosis of Cushing’s syndrome is biochemical confirmation of hypercortisolism, prior to any test of the differential diagnosis in terms of a specific cause.

Hypercortisolemia together with the loss of the normal circadian rhythm of cortisol secretion, and disturbed feedback of the HPA axis, are the cardinal biochemical features of Cushing's syndrome. Almost all tests to confirm the diagnosis are based upon these principles. Furthermore, to screen for Cushing's syndrome, tests of high sensitivity should be used initially so as to avoid missing milder cases. Tests of high specificity can then be employed to exclude false positives.

It is important to realize that the validation of the published test criteria employed have been on specific assays, and thus test responses should ideally be validated on the local assay used before the results can be interpreted in particular patients. This is aided by supra-regional and nationwide inter-assay quality control assurance (1).

Cortisol is normally secreted in a circadian rhythm, with the highest levels early in the morning and reaching their nadir levels at about midnight (<50 nmol/L or 1.8 μg/dL). In patients with Cushing’s syndrome the circadian rhythm is lost. However, most of the patients still maintain their morning values within the normal range, but have raised nocturnal levels, rendering midnight levels most useful diagnostically. The measurement of free serum cortisol is very challenging, so either levels of salivary cortisol or total serum cortisol are being used. However, exogenous estrogens and some medical conditions (see below) will increase cortisol-binding globulin and therefore total cortisol levels. Hence, in all investigations relying on a serum cortisol assay that measures total cortisol, hormone replacement therapy or the oral contraceptive pill should be stopped 4-6 weeks prior to investigation, although it is likely that a shorter time off treatment may still be effective.

DIFFERENTIAL DIAGNOSIS OF CUSHING’S SYNDROME

Once Cushing's syndrome has been diagnosed, the next step is to differentiate between ACTH-dependent and ACTH-independent causes by measurement of plasma ACTH. Modern two-site immunoradiometric assays are more sensitive than the older radioimmunoassays and therefore provide the best discrimination. Rapid collection and processing of the sample is essential as ACTH is susceptible to degradation by peptidases so that the sample must be kept in an ice water bath and centrifuged, aliquoted, and frozen within 2 hours to avoid a spuriously low result. Measurements are usually taken on two different days to avoid misinterpretation because of the episodic secretion of ACTH. The circadian rhythm of ACTH in patients having Cushing’s syndrome is lost, as it is for cortisol measurement, and the optimal sample should be taken at 08.00-09.00h (133).

It is useful to duplicate this test because patients with ACTH-dependent Cushing’s disease have been shown to have on occasion ACTH levels less than 10 ng/L (2 pmol/L) on conventional radioimmunoassay (134). The ACTH immunoassays can interfere with heterophilic antibodies or ACTH fragments and cases of falsely elevated ACTH have been reported using Immuline ACTH assay (135). Therefore, if results are inconsistent or not fitting with clinical features, ACTH should be remeasured using an alternative immunoassay.

Consistent ACTH measurements of <10 ng/L (2 pmol/L) essentially confirm ACTH-independent Cushing's syndrome and radiologic evaluation of adrenals is the next step in diagnosis. Conversely, if levels are consistently greater than 20-30 ng/L (4-6 pmol/L), Cushing's syndrome is ACTH-dependent, due to pituitary disease or ectopic ACTH/CRH secretion.

Intermediate levels are less discriminatory, but a lack of ACTH response to the CRH test (see below) may be particularly helpful in these intermediate cases.

INVASIVE TESTING

NON-INVASIVE TESTS

IMAGING

Pituitary (189)

Imaging of the pituitary is an important part of the investigation of ACTH-dependent Cushing's syndrome to identify a possible pituitary lesion and to aid the surgeon during exploration (189). However, the results must be used in conjunction with the biochemical assessment as approximately 10% of normal subjects may have pituitary incidentalomas on MRI (190). Modern MRI techniques using T1-weighted spin echo and/or spoiled gradient recalled acquisition (SPGR) techniques will identify an adenoma in up to 80% of patients with Cushing’s disease (191). They provide greater sensitivity than conventional MRI but with more false positive results (191, 192). On MRI, 95% of microadenomas exhibit a hypointense signal with no post-gadolinium enhancement (Figure 2); however, as the remaining 5% have an isointense signal post-gadolinium, pre-gadolinium images are essential (193). The delayed pituitary microadenoma contrast washout was detected on FLAIR MRI as hyperintensity in 80% of patients with Cushing's disease and negative dynamic MRI (n=5) (194).

CT has a sensitivity of only approximately 40-50% for identifying microadenomas, and is thus significantly inferior to MRI (sensitivity 50-60%) (25, 195), and it should therefore be reserved for patients in whom MRI is contraindicated or unavailable. Computerized tomography (CT) imaging typically shows a hypodense lesion that fails to enhance post-contrast.

Preoperative localization to one side of the pituitary gland by MRI had been advocated as better than BIPSS with a positive predictive value of 93% (149, 196). Other groups have found MRI less effective (148, 197). In addition, as noted above, we have found MRI often to be unhelpful in the pediatric age group, and BIPSS to be of significant value in these patients (165).

Figure 2.

Magnetic resonance scan of the head with gadolinium showing left-sided pituitary hypointense microadenoma (white arrows) in 2 different patients (T1 image post-contrast).

STRATEGY FOR THE DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF CUSHING’S SYNDROME

There have been a number of international consensus statements published for the diagnosis and differential diagnosis of Cushing's syndrome, the latest on the diagnosis in 2008 (74, 80). It is recommended that UFC (at least two measurements), the LDDST, or late-night salivary cortisol (two measurements) are used as the first line screening test. One other of these tests should confirm abnormal results (Figure 3). In patients with discordant results second-line tests should be used as necessary for confirmation. Once the diagnosis of Cushing’s syndrome is unequivocal, ACTH levels, the CRH test (combined with the LDDST or HDDST), together with appropriate imaging, are the most useful non-invasive investigations to determine the etiology. BIPSS is recommended in cases of ACTH-dependent Cushing’s syndrome where the clinical, biochemical, or radiological results are discordant or equivocal. However, in many centers where BIPSS is available and validated, the practice is to use this test in almost all cases of ACTH-dependent Cushing’s syndrome with the exception of corticotroph macroadenomas.

Figure 3.

Investigations algorithm for suspected Cushing’s syndrome; CS – Cushing’s syndrome, ONDST – overnight dexamethasone suppression test, UFC – urinary free cortisol, LDDST – low dose dexamethasone suppression test, HDDST – high dose dexamethasone suppression test, BIPSS – bilateral inferior petrosal sinus sampling, PPNAD – primary pigmented nodular adrenocortical disease, AIMAH – ACTH-independent multinodular adrenal hyperplasia.

TREATMENT OF CUSHING’S SYNDROME

Treatment should be directed toward resolving the primary cause of Cushing’s syndrome, presuming accurate differential diagnosis. Hypercortisolism, accompanied with fatal consequences if left untreated, should be controlled by all means. Whenever possible, surgery, regardless of etiology, presents a first-line treatment option aiming for a permanent cure and resolving the hypercortisolism together with its clinical consequences. However, the approach to the patient with Cushing’s syndrome is individual, so radiation therapy or even medical therapy as first-line treatment could be appropriate depending on etiology, clinical state and the personal choice of a patient.

Following treatment, all of the signs and symptoms of adrenal deficiency should be promptly corrected with steroid replacement therapy. Associated medical disorders of Cushing’s syndrome such as diabetes mellitus, osteoporosis and hypertension should be treated, aiming to avoid permanent dependence on therapy after resolving the primary cause of Cushing’s syndrome.

It should also be emphasized that in severely-unwell patients the metabolic complications should be vigorously treated as a matter of priority, including hypokalemia, hypertension and hyperglycemia. Any infections should be sought and treated. Most importantly, most centers would now advise immediate anti-coagulation with prophylactic low molecular weight heparin in all but the mildest cases or where there are contraindications (207).

Treatment of Cushing’s Disease

The first-line therapy almost always consists of transsphenoidal surgery (Figure 4). Patients with persistent Cushing’s post-operatively can be re-operated upon with a lower success rate than primary surgery and with higher rates of other pituitary hormonal deficiencies. Prior to repeated surgery it is wise to repeat diagnostic testing, especially if corticotrophinoma has not been found on pathologic examination, to exclude the possibility of a hyperglycemia missed ectopic ACTH syndrome. Besides re-operation, patients can be treated either by radiotherapy, medical therapy, or as a definitive solution to the hypercortisolism, bilateral adrenalectomy.

TRANSSPHENOIDAL SURGERY (208)

According to the relevant 2008 consensus statement on the treatment of ACTH-dependent Cushing's syndrome (209, 210), transsphenoidal surgery is widely regarded as the treatment of choice for Cushing’s disease (210). Besides the traditional microscopic approach there is an endoscopic approach which appears useful in patients with persistent or recurrent disease (211, 212) and is associated with a shorter hospital stay (213). The remission rate of Cushing’s disease due to pituitary microadenoma is similar for both techniques (around 80%, total n=6695) with better results in pituitary macroadenomas when using endoscopic approach (59.9% vs 76.3%) (214).

The procedure is not without risks, and in the European Cushing’s disease survey group of 668 patients, the perioperative mortality was 1.9%, with other major complications occurring in 14.5% (215). The frequency of reported adverse events varies widely: diabetes insipidus (either temporary or permanent) (3-46%); hypogonadism (14-53%); hypothyroidism (14-40%); cerebrospinal fluid rhinorrhea (4.6-27.9%); severe growth hormone deficiency (13%); bleeding (1.3-5%); and meningitis (0-2.8%) (215-217).

Where an adenoma is apparent at transsphenoidal exploration, a selective microadenomectomy of tumor tissue is performed, and the surgeon may be guided by pre-operative imaging. However, where no tumor is obvious, and there is no concern regarding fertility, subtotal resection of 85-90% of the anterior pituitary gland is done, leaving a small part near the pituitary stalk. However, there is still a substantial and unpredictable risk of panhypopituitarism.

Figure 4

Management algorithm of Cushing’s disease; TSA, Transsphenoidal adenomectomy; CD, Cushing’s disease.

The overall remission rate combined for microadenomas and macroadenomas in various large series is in the order of 70-79%, although higher rates of approximately 90% can be achieved with microadenomas (7, 214-216, 218-220). Remission rates are estimated upon post-operative pathologic and biochemical results, although both can be equivocal. Half of all tumors cannot be pre-operatively visualized (221), and therefore parts of the tumor can be overlooked intra-operatively and left behind affecting the surgical success rate (222). Adenomas can rise near or within pituitary stalk, rarely in ectopic locations (223, 224), and may show signs of microscopic invasion (225).

Prognostic markers of long-term remission are patient age over 25 years, a microadenoma detected by MRI, lack of invasion of the dura or cavernous sinus, histological confirmation of an ACTH-secreting tumor, low post-operative cortisol levels and long-lasting adrenal insufficiency (209).

Of patients achieving remission, about 10% of these will have a recurrence by 10 years and 20% by 20 years (226), and this emphasizes the need for long-term annual follow-up based on the same diagnostic criteria as with initial diagnostics; salivary midnight cortisol, 24-hour urinary cortisol, and an overnight 1 mg dexamethasone suppression test results. Special attention should be paid to patients with intermittent hypercortisolism (227). Transsphenoidal surgery is also a useful procedure in patients with Nelson’s syndrome to reduce tumor size, and ameliorate hyperpigmentation (228).

Thromboprophylaxis with low molecular weight heparin should be considered peri-operatively in all surgical procedures for Cushing's syndrome (91, 92).

POST-OPERATIVE EVALUATION AND MANAGEMENT

Many use glucocorticoid coverage for transsphenoidal surgery, tapering off within 1 to 3 days. Morning (09.00h) serum cortisol measurements are then obtained on day 4 or 5 post-operatively starting 20 hours after the last glucocorticoid administration, during which time the patient should be closely observed for the development of signs of adrenal insufficiency (229). However, where there is close post-operative supervision, it may be possible to assess early cortisol results in the absence of corticosteroid cover.

In the immediate post-operative period, there is a wide range of possible biochemical results, but elevated cortisol in 24-hour urine unequivocally favors operation failure with persistent disease. Post-operative hypocortisolemia (<50 nmol/L [1.8 µg/dL] at 09.00h) is probably the best indicator of the likelihood of long-term remission (230-232). However, detectable cortisol levels of less than 140 nmol/L (<5µg/dL) are also compatible with sustained remission (233-235). In cases of a mild or cyclic Cushing’s disease the normal corticotrophs may not be suppressed and sustain a normal cortisol level with a normal diurnal rhythm.

Higher post-operative cortisol levels are more likely to be associated with failed surgery; however, cortisol levels may sometimes gradually decline over 1-2 months reflecting gradual infarction of remnant tumor or a gradual loss of autonomy of the adrenal (233, 236). Regardless of the possibility of this late remission, the approach should be individualized and additional testing done prior to 3 months if there is reason to believe in residual disease. Persistent cortisol levels greater than 140 nmol/L (>5 µg/dL) 3 months after surgery require further investigation. Persistent hypercortisolemia after transsphenoidal exploration should prompt reevaluation of the diagnosis of Cushing’s disease, especially if previous diagnostic test results were indeterminate or conflicting, or if no tumor was found on pathological examination.

The treatment options for patients with persistent Cushing’s disease include: repeat surgery, radiation therapy, and bilateral adrenalectomy. If immediate surgical remission is not achieved at the first exploration, early repeat transsphenoidal surgery including the endoscopic technique may be worthwhile in a significant proportion of patients, at the expense of an increased likelihood of hypopituitarism (212, 237, 238). Repeat sellar exploration is less likely to be helpful in patients with empty sella syndrome or very little pituitary tissue on MRI scans. Patients with cavernous sinus or dural invasion identified at the initial procedure are not candidates for repeat surgery to treat hypercortisolism and should receive alternative therapy.

Patients who are hypocortisolemic should be started on glucocorticoid replacement. Hydrocortisone 15-20 mg total daily dose in three divided doses is the preferred choice by most. The largest dose (10 mg) should be taken before getting out of bed, and the last 5mg dose should be taken in early afternoon and no later than 18.00h because later administration of glucocorticoids may result in disordered sleep. This low dose of hydrocortisone should be used to avoid long-term suppression of the HPA axis. All patients receiving chronic glucocorticoid replacement therapy should be instructed that they are “dependent” on taking glucocorticoids as prescribed, and that failure to take or absorb the medication could lead to adrenal crisis and possibly death. They should be prescribed a 100mg hydrocortisone (or other high-dose glucocorticoid) intramuscular injection pack for emergency use. They should also obtain a medical information bracelet or necklace that identifies this requirement (Medic-Alert Foundation or similar). Education should stress the need for compliance with the daily dose of glucocorticoid; the need to double the oral dose for nausea, diarrhea, and fever; and the need for parenteral administration and medical evaluation during emesis, trauma, or severe medical stress.

The patient should be told to expect desquamation of the skin, and flu-like symptoms (malaise, joint aching, anorexia, and nausea) during the early post-operative months, and that these are signs that indicate remission. Symptoms can be especially prominent in patients with long-standing, severe Cushing’s syndrome. Some of these symptoms have been related to high levels of circulating interleukin-6 (239). Most patients tolerate these symptoms of glucocorticoid withdrawal much better if they are forewarned and alerted to their ‘positive’ nature. The glucocorticoid dose should not be increased in the absence of intercurrent illness based on these symptoms alone, because it constitutes iatrogenic hypercortisolism, but signs of adrenal insufficiency, such as vomiting, electrolyte abnormalities, and postural hypotension, should be excluded(240).

Recovery of the HPA axis can be monitored by measurement of 09.00h serum cortisol after omission of hydrocortisone replacement for 20 hours. Because recovery after transsphenoidal surgery rarely occurs before 3-6 months and is common at 1 year, initial testing at 3-4 to 9 months is reasonable (111). If the cortisol is undetectable on 2 consecutive days, then recovery of the axis has not occurred and glucocorticoid replacement can be restarted. If the cortisol is measurable, adequate reserve of the HPA axis can be assessed using the insulin tolerance test (231), with a peak cortisol value of greater than 500 nmol/L (>18 µg/dL), indicating adequate reserve on modern assays (241). Many centers use the cortisol response to 250 µg synthetic (1-24) ACTH (SST) as an alternative means of assessing HPA reserve (242, 243), but there is some controversy as to its reliability in this situation (243, 244). If it is used instead of the insulin tolerance test, a 30-minute cortisol of greater than 500 nmol/L is probably more reliable (241), but the cut-off value for passed SST can vary between laboratories and assays (430-550nmol/L). Glucocorticoid replacement can be discontinued abruptly if the cortisol response is shown to be normal. Where recovery of the HPA axis is only partial on dynamic testing, but the 09.00h cortisol levels are above the lower limit of the normal range (200 nmol/L [7 µg/dL]), it is reasonable to taper and stop the hydrocortisone unless symptoms of adrenal insufficiency occur. Patients need to continue to be aware of the continuing need for additional glucocorticoids at times of stress or illness and should be given a supply of oral hydrocortisone and an intramuscular injection pack. For patients with detectable but low 09.00h cortisol levels, the hydrocortisone replacement dose should be adjusted down, and a slightly lower dose may be given. Assessment of adequate replacement of hydrocortisone dosing by measuring serum cortisol at various points throughout the day, ensuring that levels are always sufficient (>100 nmol/L [>3.6 µg/dL]) before each dose, can occasionally be useful. This may mean that the peak levels after each dose appear to be unphysiological, but there is a trade-off between mirroring a normal physiologic rhythm as far as possible and the inconvenience of multiple dosing. Modified release hydrocortisone may provide more physiological replacement (245).

Two late conundrums may arise: the questions of recurrence and permanent lack of recovery of the axis. Patients who articulate that the Cushing’s syndrome has returned are often correct, even before physical and biochemical evidence are unequivocal. Investigation is warranted in a patient with these complaints or with recurrent physical signs characteristic of hypercortisolemia. UFC can be measured initially on dexamethasone 0.5 mg/day, if not yet weaned from glucocorticoids. Measurement of late-night salivary cortisol having omitted the afternoon dose of hydrocortisone may also be useful. However, ideally assessment of a cortisol circadian rhythm can be done as an inpatient having stopped the hydrocortisone completely.

If recurrent Cushing’s disease is diagnosed, the therapeutic options are the same as for persistent disease. It should be remembered when investigating recurrence that long-standing ACTH stimulation by a pituitary adenoma causing macronodular adrenal hyperplasia may subsequently involve semi-autonomous cortisol production (246).

If the UFC result is subnormal or low, the patient should be questioned about the actual dose of glucocorticoid that has been taken. Often, patients take additional hydrocortisone, either because they discover that this decreases the symptoms of glucocorticoid withdrawal or because they have increased the dose “for stress,” often without following strict guidelines. These patients have a suppressed axis and very slow regression of Cushingoid features because of exogenous hypercortisolism. They require education and support along with reduction in the daily dose of hydrocortisone to recommended levels. The patient who has a subnormal cortisol response to ACTH 3 years after transsphenoidal surgery (in the absence of over-replacement) is likely to proceed to life-long ACTH deficiency, but this is also highly indicative of a lack of recurrence long-term.

Post-operatively, assessment for deficiencies of other pituitary hormones should also be sought, and the appropriate replacement regimen initiated as necessary, especially growth hormone deficiency in children.

Diuresis is common after transsphenoidal surgery and may result from intraoperative or glucocorticoid-induced fluid overload or may be due to diabetes insipidus. For these reasons, assessment of paired serum and urine osmolality and the serum sodium concentration is essential. It is advisable to withhold specific therapy unless the serum osmolality is greater than 295 mOsm/kg, the serum sodium is greater than 145 mmol/L, and the urine output is greater than 200 mL/hour with an inappropriately low urine osmolality. Desmopressin (DDAVP, Ferring) 0.5-1 µg given subcutaneously will provide adequate vasopressin replacement for 12 hours or more. Hyponatremia may occur in as many as 20% of patients within 10 days of surgery. This may be due to injudicious fluid replacement or the syndrome of inappropriate antidiuretic hormone secretion (SIADH) as is frequently seen after extensive gland exploration, and fluid intake should be restricted (247). While transient central diabetes insipidus is common, in about 20% of operations (248), a small minority of patients proceed to permanent diabetes insipidus, requiring long-term treatment with a vasopressin analogue.

The state of permanent diabetes insipidus is usually accompanied by other anterior pituitary hormone deficiencies (249).

Many glucocorticoid-induced abnormalities, including hypokalemia, hypertension, and glucose intolerance, may be normalized during the post-operative period so that preoperative treatments for these need to be reassessed.

BILATERAL ADRENALECTOMY

Bilateral adrenalectomy is also an important therapeutic option in patients with ACTH-dependent Cushing’s syndrome not cured by other techniques, particularly in young patients desiring fertility where there are concerns over radiotherapy-induced hypopituitarism. However, it has the disadvantages of life-long glucocorticoid and mineralocorticoid replacement therapy, and increased peri-operative morbidity and mortality. The incidence of adrenal crisis following bilateral adrenalectomy throughout life is reported higher than in patients with Addison’s disease or ACTH deficiency (9.3 events per 100 patients versus 3-6 events/100 patients) (250). In the post-operative period after bilateral adrenalectomy, the hydrocortisone dose should be maintained at 50-100mg of hydrocortisone four times a day by intravenous/intramuscular injection or 200mg per 24 hours in continuous intravenous infusion (251). When no complications are seen after 48 hours post-operatively, the dose of hydrocortisone is reduced to the double replacement dose (40 mg total/day). At this stage, fludrocortisone 100-200mcg daily orally should be introduced.

In addition, the development of Nelson’s syndrome in patients with ACTH-secreting pituitary adenomas occurs in between 8% and 38% of cases (252-254). The chance of developing Nelson’s syndrome appears to be greater if adrenalectomy is performed at a younger age, and if a pituitary adenoma is confirmed at previous pituitary surgery (252, 255). Prophylactic pituitary radiotherapy probably reduces the risk of developing Nelson’s syndrome (252). However, it may be best to hold radiotherapy in reserve and undertake regular MRI scanning of the pituitary, especially when imaging has originally not shown any clear tumor (256). Others have advocated unilateral adrenalectomy plus pituitary irradiation as an alternative to bilateral adrenalectomy, as it gives similar remission rates to primary transsphenoidal surgery (257), but this should be reserved for selected cases.

PITUITARY RADIOTHERAPY (258)

For patients in whom fertility does not represent an important issue and with uncertain preoperative localization, radiotherapy may be used as primary treatment, while in patients showing no signs of remission after transsphenoidal resection of a tumor, pituitary irradiation is one of the next treatment options. It may also be considered as primary therapy for children under age 18 years, because results are comparable to surgery (259, 260). Pituitary irradiation may also decrease the occurrence of Nelson's syndrome (large, locally invasive corticotrophinomas with hyperpigmentation) after medical or surgical adrenalectomy, but this has not been tested in a prospective randomized trial (261).

Primary pituitary radiotherapy for the treatment of Cushing’s disease in adults has been shown to produce rather poor long-term remission rates of around 50% (226, 262). In contrast, as a second-line therapy to failed pituitary surgery, better results are achieved with around 80% showing long-term remission as defined by the normalization of the clinical state and biochemical parameters (263, 264). In children, however, not only primary therapy shows better results with cure rate of 80%, but also they respond more rapidly, usually within 12 months (260), while remission in adults usually occurs by two years although it can take considerably longer. Medical therapy to control hypercortisolemia is usually utilized in the interim, and patients should be reassessed at least yearly (265). In order to evaluate results of pituitary irradiation, urinary free cortisol or several serum cortisol levels throughout the day are measured and medical therapy should be stopped for several consecutive days, followed upon patient education of early recognition signs and symptoms of adrenal insufficiency in outpatient conditions.

Conventional pituitary radiotherapy using a linear accelerator is delivered at a total dose of 4500 to 5000 cGy in 25 fractional doses over 35 days using a 3-or 5-field (opposed lateral fields and vertex field) technique. Side effects when given as primary therapy are rare, but there is significant risk of growth hormone deficiency occurring early in 36-68% of treated adults, while other anterior pituitary deficiencies may develop over time (87, 263). There is some evidence of an increased risk of cerebrovascular complications, which is of concern particularly in younger patients (266), but not all studies agree and further studies are required (267).The risk of optic neuropathy is low and probably less than 1% as long as low-dose fractions are used. Although meningiomas and gliomas have been reported after pituitary radiotherapy, it is not clear whether the incidence is significantly greater than the background risk of developing such tumors (265, 268). However, the very rare and aggressive sarcomas which are sometimes seen are very likely radiation-induced.

Stereotactic radiotherapy using a gamma-knife or Cyber-knife (‘radiosurgery’) is used to optimize the tumor dose and minimize radiation to other areas by delivering a single high dose to a small tumor. This approach seeks to avoid the complications of optic neuritis and cortical necrosis associated with larger total and fractional doses (269), not to mention convenience for the patient receiving therapy in one treatment. It has been less well investigated so far, but has a number of theoretical advantages, including a possible reduction in risk of cerebrovascular disease. It is hard to make a direct comparison in effectiveness between methods because of the difference in size of the treated tumors (269, 270). Most patients still develop endocrine deficiency in the years after treatment (271-273). Because of the high dose of delivered radiation, it is not suitable for large lesions because of the large volume of exposed tissue or for lesions near to the radiosensitive tissues, such as the optic chiasm or optic nerves, because of the potential for visual damage. Otherwise, if adenoma is not close to the optic pathway, it may be superior to conventional fractionated therapy. Gamma knife radiosurgery is probably the most widely used of these techniques. As adjunctive therapy after failed transsphenoidal surgery it achieves biochemical remission in about 55%, although follow-up times have not been as long as for conventional radiotherapy (273, 274). It can also be used as salvage therapy in difficult tumors (274). Radiosurgery of the pituitary gland using proton beams has similar efficacy as second-line therapy (275), and while possibly more precise is not widely available. Cyber-knife radiotherapy for Cushing’s disease is less well described, but there are reports of some success in small numbers of patients (276). As with other forms of radiotherapy, new hormone deficiencies are the major side-effect. It should be emphasized again that stereotactic radiotherapy cannot be used when the tumor is close to the optic chiasm. There is a difference in tolerance of radiation between cranial nerves, with optic nerves most sensitive. A dose above 8Gy should be avoided and a clearance of 5mm from the optic nerves is required, while in case of other cranial nerves doses of 19-23Gy are acceptable (277).

MEDICAL THERAPY OF CUSHING’S DISEASE

Although the primary therapy of hypercortisolism in Cushing’s disease is surgical, medical therapy can be required in cases when surgery is delayed, contraindicated, or unsuccessful. The most commonly used therapy is adrenal enzyme inhibitors, but there are other possibilities (please see below “Medical therapy in Cushing’s syndrome).

Medical Therapy of Cushing’s Syndrome

The role of medical treatment of Cushing’s syndrome is an important one. It is the routine practice of many groups to pre-treat Cushing's syndrome patients prior to surgical treatment to reverse the hypercortisolemia and its metabolic sequelae, and to hopefully reduce the complications of the definitive procedure. Similarly, medical treatment is desirable in patients with Cushing's disease whilst awaiting for pituitary radiotherapy to take effect. In patients where surgery and/or radiotherapy have failed, medical management is often essential prior to (or long-term as an alternative to) bilateral adrenalectomy. Sometimes, in the occult ectopic ACTH syndrome, it may not always be possible to identify the source of secretion, and therefore medical management is desirable pending re-investigation. Finally, medical therapy is helpful as a palliative modality in patients with metastatic disease-causing Cushing's syndrome.

The most commonly used agents are adrenal enzyme inhibitors, but adrenolytic agents, pituitary-targeted therapies or glucocorticoid-receptor antagonists are also used (Table 4). Drugs can be used in combinations in lower doses, aiming for side effect reduction with synergistic effects.

When determining the approach to treatment, the first step is to determine whether the final goal is reducing the level of serum cortisol within normal values or complete cortisol secretion blockade. The latter approach is convenient for patients with more variable secretion, while patients showing less variability can benefit more from lowering the values to the normal range and therefore avoiding the necessity of steroid replacement therapy, as well as a possibility of side effects connected to the higher dosages required with that strategy. A meta-analysis of 35 studies including 1520 patients reported pooled effectiveness of most commonly used medical agents in treatment of Cushing's syndrome with mitotane being most effective in normalizing cortisol levels in 81.8% of patients and cabergoline being least effective and normalizing cortisol in 35.7% (298). However, as noted below, mitotane is not a simple drug to use or monitor. The use of multiple agents achieved normalization of cortisol in 65.7% of patients.

ADRENAL ENZYME INHIBITORS

These agents are primarily used as inhibitors of steroid biosynthesis in the adrenal cortex (Figure 5), and thus can be utilized in all cases of hypercortisolemia regardless of cause, but most commonly in ACTH-dependent forms, often with rapid improvement in the clinical features of Cushing's syndrome. The most commonly used agents are metyrapone, ketoconazole, and in certain circumstances etomidate. In the UK ketoconazole and metyrapone are licensed for the treatment of Cushing's syndrome, while mitotane is licensed for the treatment of hypercortisolemia due to adrenocortical carcinoma. The use of etomidate or mifepristone in Cushing's syndrome is off-licence. However, the regulations are very nation-specific. When used in combinations, they have a synergistic therapeutic effect, lowering the rate of side effects.

Figure 5

Steroidogenesis with main adrenal enzyme inhibitors point of action marked; SCCE – side-chain cleavage enzyme, HSD – hydroxysteroid dehydrogenase, OH – hydroxylase, DHEA – dehydroepiandrosterone.

Metyrapone

Metyrapone acts primarily to inhibit the enzyme 11β-hydroxylase, thus blocking the production of cortisol from 11-deoxycortisol in the adrenal gland (299) (Figure 5). As a consequence to blockade of cortisol synthesis, levels of adrenal androgens and deoxycorticosterone rise. The subsequent elevation of 11-deoxycortisol can be monitored in the serum of patients treated with metyrapone. It should be noted that there may be cross-reactivity from 11-deoxycortisol with some cortisol radioimmunoassays: this may result in an unnecessary increase in the metyrapone dose and subsequent clinical hypoadrenalism (300). It is preferable to measure the serum cortisol via liquid chromatography-tandem mass spectrometry in patients treated with metyrapone (301). The fall in cortisol is rapid, with trough levels at 2 hours post-dose, and sometimes administration of a test dose of 750 mg with hourly cortisol estimation for 4 hours is performed, although not strictly necessary in our opinion (302). Maintenance therapy is usually in the range 500-6000 mg/day in 3-4 divided doses daily. Metyrapone has been used to good effect to reduce the hypercortisolemia in patients with Cushing's syndrome from adrenal tumors, the ectopic ACTH syndrome and Cushing's disease. In the former, patients can be very sensitive to low doses of this agent, whilst in Cushing’s disease higher doses are often required. In Cushing's disease this can be due to the compensatory rise in ACTH in patients not having received pituitary radiotherapy. During short-term follow-up (1-16 weeks) of 54 patients with Cushing’s disease, cortisol normalized on the metyrapone treatment in 75% of participants and in 81% of 16 patients with adrenocortical carcinoma or adenoma (302).

There have not been serious maternal or perinatal complications connected with the use of metyrapone in pregnant women, but the question of safety remains open (303-305).

The principal side effects with metyrapone are hirsutism and acne (as predicted by the rise in adrenal androgens) and reported by 70-83% of women, dizziness and gastrointestinal upset occurring in 5% and 15% respectively. Because of the androgen effect the drug is not considered appropriate for the first-line therapy of long-term treatment in women (306, 307). However, it is hypoadrenalism that remains the most important potential problem, and careful monitoring of treatment and education of the patient is required. If there is uncertainty as to whether the measured cortisol is valid, and not over-estimated by cross-reactivity, it may be appropriate to consider a ‘block-and-replace’ regimen.

Hypokalemia, oedema and hypertension due to salt retention because of mineralocorticoid activity of raised levels of 11-deoxycorticosterone are infrequent (302), but may require cessation of therapy (308).

Ketoconazole

Ketoconazole is an imidazole derivative originally developed as an oral anti-fungal agent. It is a potent inhibitor of sex steroids (androstendione and testosterone) production by its action on C17-20 lyase, and cortisol secretion by 11β-hydroxylase inhibition (309-311). It also inhibits 17-hydroxylase and 18-hydroxylase activity, amongst other enzymes (312). It has also been reported to have a direct effect on ectopic ACTH secretion from a thymic carcinoid tumor (313), and possibly corticotroph ACTH release.

The treatment for Cushing's syndrome is usually started at a dose of 200 mg twice daily, with an onset of action that is probably slower than metyrapone. The usual maximum dose is 400 mg three times a day.

It has been used successfully to lower cortisol levels in patients with Cushing's syndrome of various etiologies including adrenal carcinoma, the ectopic ACTH syndrome, and invasive ACTH-producing pituitary carcinoma, with doses required between 200-1200 mg/day in up to 4 divided daily doses (314, 315), although 2-3 times daily is more usual. Although there have not been consequences on human fetuses, considering animal teratogenity and toxicity the drug is not recommend for use during pregnancy (305, 316, 317).

The normalization of cortisol levels was achieved in 71.1% of patients in pooled meta-analysis of all causes of Cushing's syndrome including 220 individuals and in 49% of patients with Cushing’s disease (298).

The principal side effect of ketoconazole is hepatotoxicity (318, 319). A reversible elevation of hepatic serum transaminases occurs in approximately 5-10% of patients, with the incidence of serious hepatic injury at around 1 in 15,000 patients (320). The hepatotoxicity appears to be idiosyncratic, but has been reported within 7 days of the initiation of treatment in a patient with Cushing's syndrome (321). Prior to the start of therapy liver function tests should be performed. The alanine aminotransferase (ALT) level should be monitored weekly within the first month of therapy, then once a month in the following trimester and afterwards sporadically or when the dose is changed. If levels reach 3-times above the upper normal range, therapy should be discontinued. Other adverse reactions of ketoconazole include skin rashes and gastrointestinal upset, and one must always be wary of causing adrenal insufficiency (321-323).

Ketoconazole is a CYP3A4 inhibitor and increases the availability of medications metabolized by that enzyme. Hence, the reduction of the dose of affected medications maybe required. Ketoconazole is a mixture of levo- and dextro- enantiomeric forms. Currently, the levo-enantiomer of ketoconazole is under clinical trial as it may be less likely to be hepatotoxic than the racemic mixture (see below).

Due to its C17-20 lyase inhibition and consequent anti-androgenic properties, ketoconazole is particularly useful in female patients where hirsutism is an issue, which may be worsened with metyrapone. Conversely, gynecomastia and reduced libido in male patients may be unacceptable as a first-line long-term treatment and require alternative agents. However, replacement therapy is an option. On the other hand, women having lower levels of estradiol and testosterone do not experience clinically manifest disorder because of the usually present menstrual irregularity. Ketoconazole requires gastric acid for absorption, so should not be given with proton-pump inhibitors. One further advantage of ketoconazole is its inhibition of cholesterol synthesis, particularly LDL cholesterol (324), and in 34 patients with Cushing's syndrome the mean total cholesterol was reduced from 6.1 to 5.0 mmol/l on ketoconazole (322).

The triazole antifungal, fluconazole can also be effective in treatment of Cushing’s syndrome, but experience is limited to single case reports. They described an effective control of hypercortisolism on 200-1200mg daily dose of fluconazole (325, 326). Fluconazole was reported in vitro to be 40% less effective in inhibition of 11β-hydroxylase and 17-hydrohylase than ketoconazole (327). The side effects of fluconazole are similar to those of ketoconazole.

Etomidate

Etomidate is an imidazole-derived anesthetic agent which was reported to have an adverse effect on adrenocortical function in 1983 (328). Compared to the other imidazole derivative ketoconazole, etomidate more potently inhibits adrenocortical 11β-hydroxylase, has a similar inhibition of 17-hydroxylase, but has less of an effect on C17-20 lyase (329). At higher concentrations it also appears to have an effect on cholesterol side-chain cleavage (330, 331).

Following their initial report in 1983, Allolio and colleagues showed that intravenous non-hypnotic etomidate dose (2.5 mg/hour) normalized cortisol levels in 5 patients with Cushing's syndrome of various etiologies (332). Since then, there have been a number of case reports on the use of etomidate in successfully reducing hypercortisolemia in seriously-ill patients with either Cushing's disease or the ectopic ACTH syndrome (333-336).

It is usually given at a dose of 2.5-3.0 mg/hour, which is adjusted based on the serum cortisol levels. It usually takes several hours for cortisol to be lowered to within the normal range (337). Etomidate is an effective agent that acts rapidly, but is limited in its use by the fact it has to be given parenterally and requires intensive care settings to safely manage and monitor cortisol and potassium levels 4-6 hourly to adjust the infusion rate (338). A simultaneous infusion of hydrocortisone of 0.5-2 mg/h may be required to maintain normal cortisol levels. However, in this situation it may be lifesaving. The preparation available in the USA contains the vehicle propylene glycol with the potential for nephrotoxicity, as opposed to the preparation available in Europe which contains alcohol.

Mitotane

Mitotane (o’p'DDD), an isomer of DDD (belonging to the same family of chemicals as the insecticide DDT), was developed following the observation of adrenal atrophy in dogs administered DDD. Mitotane inhibits steroidogenesis by reducing cortisol and aldosterone production by blocking cholesterol side-chain cleavage and 11β-hydroxylase in the adrenal gland (339). It also acts as an adrenolytic drug, causing medical adrenalectomy, after being metabolized into an acyl chloride that binds in mitochondria and causes necrosis of adrenocortical cells (340).

Mitotane is used as a treatment for adrenal carcinoma and causes tumor regression and improved survival in some patients (341, 342), and has a beneficial effect on endocrine hypersecretion in approximately 75% of patients (343). It is also utilized in Cushing's syndrome of non-malignant origin, and in this regard lower doses can be utilized (up to 4 g/day), thus reducing the incidence of side effects, particularly gastrointestinal (344). At these lower doses the onset of the cortisol-lowering effect takes longer (6-8 weeks) than with higher doses. Mitotane should not be used in pregnant women, and reproductively active women must use reliable contraception while on therapy (345).

The pooled meta-analysis of all causes Cushing's syndrome including 173 patients reported the normalization of cortisol levels on mitotane treatment in 79.8% of all patients and in 81.8% of participants with Cushing’s disease (298).

The main side effect of mitotane treatment include nausea, vomiting and lethargy. One problem even with low-dose mitotane is the hypercholesterolemia (principally an increase in LDL-cholesterol), which appears to be due to the impairment of hepatic production of oxysteroids, normally a brake on the enzyme HMG CoA reductase (346). However, simvastatin, an HMG CoA reductase inhibitor, can reverse the hypercholesterolemia, and it or a similar agent should be used if necessary in patients treated with mitotane. Other side effects of mitotane include neurological disturbance; elevation of hepatic enzymes; hypouricemia; gynecomastia in men; and a prolonged bleeding time (343, 347). Most importantly, it elevates cortisol-binding globulin, such that levels of total serum cortisol are misleading. Control should be titrated on urinary free cortisol or salivary cortisol. A monitoring of serum levels of mitotane should be undertaken due to its narrow therapeutic window and the risk of toxicity. In the long-term, measurement of blood levels can allow dose titration and reduction as appropriate. A therapeutic level of 14-20 mg/L has been recommended for adrenocortical carcinoma, but lower levels can be sought for simple control of elevated cortisol levels. Mitotane is taken up by fatty tissues, sometimes being released gradually several months after discontinuing therapy, therefore requiring adjustments in glucocorticoid therapy dosage (348). Mitotane shows cytotoxic activity on both normal and tumorous tissue causing primary adrenal insufficiency and therefore requiring glucocorticoid replacement therapy. It tends to spare the zona glomerulosa, but in a long-term use mineralocorticoid replacement is also needed (349). In general, despite effective in other forms of Cushing syndrome, its use has been limited outside of adrenal carcinoma, in which cases it has recently been shown to prolong life (342).

Table 4.

Currently Available Medical Therapy for Cushing’s Syndrome (CS)

View in own window

Medication	Action	Dosage	Side effects	Contra-indications	Comments
Steroidogenosis inhibitors
Metyrapone	11β-hydroxylase inhibitor	250-1000mg tds-qds, max 6g/day po	Nausea, vomiting, acne, hirsutism, hypo- or hypertension, oedema, hypokalemia	Pregnancy, breast-feeding, porphyria, severe liver impairment	1st line treatment when available, avoid long-term use in young women
Ketoconazole	11β-hydroxylase and 17,20-lyase inhibitor,	200-400mg tds po	Gynecomastia, alopecia, hypogonadism in men, hepatotoxicity, Gastrointestinal symptoms, rash	Liver impairment, pregnancy/ breast-feeding, porphyria	Slow in onset of action, 1st line in children, stop PPI/H2-antagonist as gastric acid needed for absorption
Mitotane	Adrenolytic	500-1000mg tds-qds, gradually increased from 500-1000mg/day to max 6g/day po	Gastrointestinal symptoms, deranged LFTs and TFTs, hyper-cholesterolemia, ataxia, orthostatic hypotension	Pregnancy/ breast-feeding, stage 4-5 renal failure, severe liver impairment	Slow in action, hyperglycemia, mitotane level monitoring required, accumulates, now rarely used for CD, high rate of withdrawal due to intolerance
Etomidate	11β-hydroxylase inhibitor	0.01-0.5mg/kg/h iv	Sedation, nausea and vomiting, temporary uncontrolled muscle movements, rash, angioedema	Pregnancy, breast-feeding, porphyria	Parenteral, rapid onset of action, anesthetic agent so ITU settings required, frequent monitoring of cortisol and K+
Modulators of ACTH release
Cabergoline	Dopamine agonist	1-7mg/week po	postural hypotension, nausea, increased tendency of gambling, hallucinations, oedema, depression, possibility of heart valve sclerosis (only very high doses)	Porphyria, pregnancy, hyper-sensitivity to ergot derivates, valvulopathy	Effective in <40% of patients, which wears off with time, cheap
Pasireotide	Somatostatin analogue	600-900μg twice daily sc	Hyperglycemia, cholelithiasis, diarrhea, headache	Severe liver impairment, Avoid in poorly controlled diabetes	Effective only in mild CD, treatment of hyperglycemia frequently required
Glucocorticoid receptor antagonist
Mifepristone	Glucocorticoid receptor antagonist	300-1200mg daily po	nausea, vomiting, dizziness, headache, arthralgia, increased TSH, decreased HDL, endometrial thickening, rash, oedema	Severe asthma, porphyria, renal failure, severe liver impairment, breast-feeding	Cortisol and ACTH levels remain high so hypokalemia may persist, also anti-progesterone, monitoring difficult

CBG – cortisol binding globulin, CD – Cushing’s disease, tds – 3 times a day; qds – 4 times a day, LFTs – liver function tests, TFTs – thyroid function tests, PPI – proton pump inhibitor, K+ - potassium, ACTH – adrenocorticotrophin hormone, po – orally, iv- intravenous, sc – subcutaneous, ITU – intensive care unit.

MODULATORS OF ACTH RELEASE

Pasireotide

Somatostatin receptors have been demonstrated on both corticotroph adenomas, and some ectopic ACTH-secreting tumors. However, although octreotide has been helpful in reducing ACTH and cortisol levels in selected case reports of ectopic ACTH-secreting tumors there has been much more limited success in patients with Cushing's syndrome probably through down-regulation of receptor sub-type 2 in these tumors by hypercortisolemia (350).

Recently, there has been renewed interest with the introduction of pasireotide, a somatostatin analogue with a broader spectrum of activity for somatostatin receptor subtypes, including type 5, which is not down-regulated during hypercortisolemia. Ever since this agent was shown in vitro to reduce human corticotroph proliferation and ACTH secretion (351, 352), there have now been a number of clinical trials published. In an initial phase II trial, pasireotide 600µg injected twice daily for 15 days reduced UFC levels in 76% of 29 patients and normalized levels in 17% (353). A multicenter phase III dose-randomized trial in 162 patients with either new, persistent, or recurrent Cushing's disease has presented 12-month results. At six months there was a reduction in UFC levels in 91 of 103 evaluable patients, with a median UFC reduction of 48%. Normalization of UFC levels were achieved in 14.6% of patients on the 600µg dose twice daily, and 26% of patients on the 900µg twice-daily dose. Patients who showed <50% reduction in UFC levels from baseline by month two were unlikely to show improvement by month 6 or 12. The most clinically relevant adverse events were hyperglycemia (73%), with 46% developing frank diabetes mellitus related to decreases in both insulin and incretin secretion, and hypocortisolemia (8%) (353, 354). Other side effects included elevated liver enzymes, cholelithiasis, nausea and diarrhea in the rate expected from experience with other somatostatin analogues (354). There is now also experience with pasireotide long-acting repeatable (pasireotide LAR), a monthly injection of 10 or 30mg, reporting around 41% of patients achieving normal UFC levels at 7 months of treatment and similar safety profile to the subcutaneous form (355). More than a 20% reduction in size of the pituitary adenoma was described in 45% of patients and an increase by more than 20% in 10% of individuals (355). Pasireotide is not recommended as a first-line treatment but can be considered as add-on therapy or second-line treatment if other medications are not tolerated. In cases where there is no clinical response, it should be discontinued.

Pasireotide at a lower dose of 250 µg three times daily has also been used in stepwise combination therapy with the dopamine agonist cabergoline (previously been demonstrated to have modest but variable efficacy as monotherapy in Cushing's disease (356), and ketoconazole. Pasireotide monotherapy induced normalization of UFC levels in 5 of 17 patients (29%). The addition of cabergoline normalized UFC levels in an additional 4 patients (24%). The further addition of ketoconazole in the remaining 8 patients induced normalization of UFC levels in 6 of these. Thus, in total, remission was achieved in 88% of patients using combination therapy out to 80 days treatment (356).

Therefore, pasireotide represents a potential new treatment for mild Cushing's disease or in combination therapy for individuals with higher hypercortisolemia, although the frequency of hyperglycemia is of major concern.

Corticotroph adenomas with USP8 mutations had been reported to have higher SST5 receptors expression which may suggest higher response rate to pasireotide treatment in this subgroup (357).

Cabergoline

The presence of dopamine receptors (D2) on around 80% of corticotroph adenomas supported use of cabergoline in patients with Cushing’s disease (358). Cabergoline at the dose of 1-7mg weekly was reported to control hypercortisolemia due to Cushing’s disease in 25-40% of patients in small case series (359). It is usually well tolerated and the most common side effects include nausea and dizziness. At the doses used for the treatment of pituitary tumors, the incidence of cardiac valve sclerosis and subsequent regurgitation was not increased in one large study, and therefore echocardiograms are not routinely needed unless high, long-term dose is required (360). However, escape is seen in some patients, so the precentage of patients with long-term control is low.

Temozolomide

Temozolomide is an oral alkylating prodrug that is converted in vivo to the DNA repair inhibitor, dacarbazine. Traditionally, this chemotherapy agent has been used in the treatment of malignant gliomas, but recent evidence suggests it is also useful in selected aggressive pituitary tumors including corticotroph pituitary carcinomas (361, 362). Although, some reports suggested that the response to temozolomide in pituitary tumors can be predicted by low expression of the DNA repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT), possibly related to MGMT gene promotor methylation (363, 364), not all studies have confirmed this (365, 366). However, the therapeutic response can usually be determined after 3 cycles of chemotherapy.

OTHER AGENTS

Retinoic Acid

Retinoic acid has been found to inhibit ACTH-secretion and cell proliferation both in vitro in ACTH-producing tumor cell lines, and cultured human corticotroph adenomas, and in vivo in nude mice (367). However, clinical trials in man are limited, and it is unlikely to be a major contributor to control.

Rosiglitazone

The thiazolidinedione rosiglitazone, a PPAR-γ agonist, was shown in supra-pharmacological doses to suppress ACTH secretion in human and murine corticotroph tumor cells. In addition, the development of murine corticotroph tumors, generated by subcutaneous injection of ACTH-secreting AtT20 cells, were prevented (368). It appears this is not specific to corticotroph adenomas, but also applies to other forms of pituitary tumor (369). However, the results in human subjects with Cushing's disease have been disappointing (370-372). This may be because doses used in the animal studies were much higher than the equivalent licensed dose in humans. Its use cannot be recommended, and indeed for other reasons it has now been withdrawn from the market.

In the rare causes of Cushing’s syndrome due to bilateral macronodular adrenal hyperplasia (BMAH) and aberrant receptor expression of GIP, β-adrenergic and LH/hCG receptors, specific receptor antagonists may prove to be useful (373). Although octreotide has been shown to have cause a therapeutic response in GIP-related AIMAH as mentioned above (28), others have found neither this somatostatin analogue nor pasireotide to be helpful in inducing a sustained response (374).

Osilodrostat (LCI699)

Osilodrostat is a novel steroidogenesis inhibitor. It is a selective inhibitor of 11β-hydroxylase, an aldosterone synthase and a non-steroidal aromatase. It causes a decrease in cortisol and aldosterone levels and an increase of 11-deoxycorticosterone and 11-deoxycortisol. LCI699 was evaluated in phase II trial as a potential anti-hypertensive agent in patients with primary hyperaldosteronism and essential hypertension (375). In 10-week study in patients with Cushing's disease (n=12) who were not cured by previous surgery, osilodrostat normalized UFC in 92% of subjects with more than 50% decrease in UFC in all participants (376). In 22-week phase II trial in patients with Cushing’s disease (n=19) and UFC >1.5 of the upper normal limit, osilodrostat (10-60mg/day) normalized UFC in 79% of patients. It also produced no significant change in blood pressure and an increase of ACTH 3-4-fold. Adrenal insufficiency was seen in 32% of subjects leading to the reduction of the LCI699 dose, while an increase of testosterone and hirsutism was reported in around 30% of women (376). The phase III study was a double-blind randomized trial with a withdrawal phase after 24 weeks of treatment followed by continuation of osilodrostat mean dose of 5mg twice a day from 40 to 48 weeks (377). Fifty three percent of participants in the osilodrostat arm (n=36) maintained UFC in the normal range without increasing the dose at 24 weeks, compared to 29% in the placebo group (n=35). Sixty-six patients were not randomized to withdrawal of treatment and continued osilodrostat due to higher cortisol levels. Of 137 individuals with Cushing's disease, 66% maintained UFC in the normal range after 48 weeks (6 months) (377). Most frequent side effects included nausea (42%), headache (34%), fatigue (28%) and adrenal insufficiency (28%). FDA approved osilodrostat for treatment of Cushing's disease in March 2020 and it may prove to be a useful and more convenient alternative to metyrapone.

Levoketoconazole

Levoketoconazole is a stereoisomer of ketoconazole and its efficacy and safety has been assessed in the phase III open-label trial of 94 individuals with Cushing's syndrome (85% with Cushing’s disease) and mean UFC 4.9 times upper normal range (378).The starting dose was 150mg twice a day and titrated up to a total daily dose of 1200mg aiming for normal UFC. Eighty one percent of participants achieved UFC in the normal range by the end of titration phase and 31% maintained it by 6 months of treatment. Most common adverse effects were nausea (32%), headache (28%) and deranged liver function in 11% of participants. However, it remains to be seen whether it proves in practice to be less hepatotoxic than the racemic mixture.

Glucocorticoid Receptor Antagonist(s)

Mifepristone (RU 486), as a potent antagonist of glucocorticoid and progesterone receptors, blocks the peripheral actions of glucocorticoids and progestogens (379, 380). As a consequence it also blocks glucocorticoid-induced negative feedback at the hypothalamo-pituitary level, inducing a rise in ACTH, arginine-vasopressin (AVP) and hence cortisol (381). It has occasionally been given to patients with all forms of Cushing's syndrome (382, 383), showing effectiveness in rapidly reducing symptoms of cortisol-induced psychosis (384, 385), and the metabolic benefit of glycemic control and hypertension have been established (383). Although, it has proven to be effective in the treatment of hypercortisolemia symptoms and signs (382, 386), the major drawback is the lack of biochemical markers to asses either therapeutical effectiveness or possible hypoadrenalism. Adrenal insufficiency is challenging to treat, because the drug, besides blocking endogenous cortisol, also blocks the action of synthetic steroids as replacement therapy. Hypokalemia is a frequent problem due to the saturation of 11β-HSD type 2 and cortisol action on the mineralocorticoid receptor, although it responds well to spironolactone. The daily dose of mifepristone ranges between 300 and 1200mg. It showed a significant improvement of glucose and HbA1c in 60% of patients with impaired glucose tolerance or diabetes (383). Mifepristone could be used as add-on therapy for Cushing’s syndrome with associated hyperglycemia. Endometrial thickening and vaginal bleeding secondary to the anti-progestin effect are likely to be seen in women. However, a new derivative of mifepristone with less anti-progestogen blocking activity, relacorilant, is currently under trial.

Relacorilant (CORT125134)

Relacorilant is a glucocorticoid receptor inhibitor with no action on progesterone receptor. A phase II study (GRACE) included 130 patients with Cushing’s syndrome and type 2 diabetes and/or hypertension. Half of the patients receiving higher dose (range of 100mg-400mg daily) of relacorilant for 16 weeks had HbA1c reduced by ≥0.5% or dose of insulin/sulphonylurea reduced by ≥25%. The reduction of systolic BP by at least 5mmHg was reported in 64% of participants receiving higher dose of medication. Publication of the results of phase II & III studies are awaited (NCT03697109).

It should be noted that the use of all these novel agents may be limited by their expense and availability.

MONITORING TREATMENT

It is important to monitor all patients on medical therapy for Cushing’s syndrome in order to assess the effectiveness of treatment, and in particular to avoid adrenal insufficiency. Serum cortisol level and/or urine cortisol level are used in order to estimate steroid inhibitor therapy. One way is to assess the mean of 5 serum cortisol measurements across the day, although others favor measurement of urinary free cortisol (UFC). A mean serum cortisol between 150 and 300 nmol/L (5.5-11 μg/dL) corresponds to a normal cortisol production rate (387), and this range should be the aim of therapy, although this figure may be an overestimate as it is based on older cortisol assays. As mentioned above, a liquid chromatography tandem mass spectrography cortisol assay is preferable in patients on metyrapone.

When mitotane is used, only measurement of 24-hour urinary free cortisol reflects therapy effectiveness and concentration of serum free cortisol, because mitotane reduces 17-OHCS excretion, which therefore cannot stand for correct measurements. Because it raises the level of cortisol binding globulin (CBG), the level of total serum cortisol is inappropriate for monitoring of cortisol secretion, as it can be two to threefold elevated (388, 389). The high level of CBG explains why replacement dosage of steroids needs to be increased in case of an adrenal insufficiency, although these is also a contribution from increased hepatic steroid metabolism.

CUSHING’S SYNDROME IN SPECIFIC GROUPS

PROGNOSIS AND COURSE AFTER EFFECTIVE TREATMENT

Before treatment was readily available, the mortality rate for Cushing’s syndrome was 50% after the first symptoms appeared, mainly due to cardiovascular, thromboembolic, infectious or hypertensive complications (421).

Even today, patients with severe hypercortisolism have an raised mortality rate due to increased coagulability and it’s the consequences or opportunistic infections (101, 422, 423), emphasizing the need for taking over the hormonal control as soon as possible. The prognosis is mainly a reflection of the underlying condition. The life expectancy of patients with non-malignant causes of Cushing's syndrome has improved dramatically with effective surgical and medical treatments.

Even when cured by strict criteria, Cushing’s disease may often recur over time (424).

From a number of studies in patients with Cushing’s disease treated in the era of transsphenoidal surgery, it initially appeared that after curative transsphenoidal surgery long-term mortality was not significantly different from that in the general population (423, 425). However, another population based study suggested that mortality is marginally increased (3),while even more recently a very significantly increased mortality was shown even in patients who remained cured. A large European Registry of 1564 patients with Cushing’s syndrome, including 1045 patients with Cushing's disease, reported 3.1% 90-day mortality in this group generally (426). The main cause of death was progression of the main disease (36%), infections (31%), and cardio- and cerebrovascular disease (17%). As expected, the highest mortality was in individuals with ectopic Cushing's syndrome (20.2%), 2.2% in patients with Cushing's disease and 1.6% in those with ACTH-independent Cushing's syndrome.

However, a large-scale meta-analysis showed that patients with Cushing’s disease who were cured at their first operation showed a normalized standardized mortality ratio, further emphasizing the importance of this modality of treatment and the necessity for an experienced surgeon. Nevertheless, while abdominal obesity may improve, hypertension and insulin resistance leading to increased cardiovascular risk with evidence of atherosclerotic disease persists when measured 5 years after remission of Cushing’s disease (87). It is therefore important to aggressively treat associated conditions such as hypertension and diabetes even when the Cushing’s per se has been controlled. Unlike some signs and symptoms that disappear gradually over the next year after successful treatment, co-morbidities such as diabetes mellitus and hypertension improve, but may not resolve completely, requiring further aggressive treatment. There is also some evidence that the outcome from Cushing's disease may be worse in males (47). Some of the signs and symptoms of Cushing’s syndrome are expected to disappear gradually over the following year after the treatment; skin thickness improves in weeks, but for some it may take longer, as does muscle strength.

The outcome of pediatric Cushing’s disease is excellent if treated at centers with appropriate experience (399, 427).

Cushing's syndrome results in significant impairment in quality of life (428, 429), psychiatric symptoms (430) and cognitive deficits (431), as previously noted. However, in general these are only partially improved with treatment, but often do not resolve completely in either children or adults.

There is some evidence that deficits in bone mass may be partially reversed after treatment of hypercortisolemia (432, 433). Bisphosphonate treatment may induce a more rapid improvement in bone mineral density (434), and should be considered (along with calcium and vitamin D supplements), but it is unclear whether they are needed for the majority of patients with osteoporosis. Osteoporosis starts to improve after 6 months, with rapid improvement over the next two years, but with the possibility of residual disease to some extent (435). However, in general the prognosis is good without any specific treatment, and the care should be expectant.

The prognosis of the potentially malignant causes of Cushing's syndrome is more variable. Adrenal cancer associated with Cushing's syndrome has an extremely poor prognosis. Tumors that produce ectopic ACTH tend to have a poorer prognosis, compared with tumors from the same tissue that do not produce ACTH. Small cell lung cancer, islet cell tumors and thymic carcinoids illustrate this phenomenon: up to 82% of patients with small cell lung cancer and Cushing’s syndrome were reported to die within 2 weeks from the start of chemotherapy (436), although currently a survival in terms of months should be expected.

REFERENCES

1.

Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev. 1998;19(5):647–72. [PubMed: 9793762]

2.

Storr HL, Chan LF, Grossman AB, Savage MO. Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances. Trends Endocrinol Metab. 2007;18(4):167–74. [PubMed: 17412607]

3.

Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994;40(4):479–84. [PubMed: 8187313]

4.

Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86(1):117–23. [PubMed: 11231987]

5.

Gicquel C, Le Bouc Y, Luton JP, Girard F, Bertagna X. Monoclonality of corticotroph macroadenomas in Cushing's disease. J Clin Endocrinol Metab. 1992;75(2):472–5. [PubMed: 1322426]

6.

Biller BM, Alexander JM, Zervas NT, Hedley-Whyte ET, Arnold A, Klibanski A. Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing's disease. J Clin Endocrinol Metab. 1992;75(5):1303–9. [PubMed: 1358909]

7.

Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med. 1988;109(6):487–93. [PubMed: 2843068]

8.

Young WF Jr, Scheithauer BW, Gharib H, Laws ER Jr, Carpenter PC. Cushing's syndrome due to primary multinodular corticotrope hyperplasia. Mayo Clin Proc. 1988;63(3):256–62. [PubMed: 2830441]

9.

Holthouse DJ, Robbins PD, Kahler R, Knuckey N, Pullan P. Corticotroph pituitary carcinoma: case report and literature review. Endocr Pathol. 2001;12(3):329–41. [PubMed: 11740054]

10.

Gaffey TA, Scheithauer BW, Lloyd RV, Burger PC, Robbins P, Fereidooni F, et al. Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg. 2002;96(2):352–60. [PubMed: 11838811]

11.

Dahia PL, Grossman AB. The molecular pathogenesis of corticotroph tumors. Endocr Rev. 1999;20(2):136–55. [PubMed: 10204115]

12.

Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, et al. Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nat Genet. 2015;47(1):31–8. [PubMed: 25485838]

13.

Doppman JL, Nieman LK, Travis WD, Miller DL, Cutler GB Jr, Chrousos GP, et al. CT and MR imaging of massive macronodular adrenocortical disease: a rare cause of autonomous primary adrenal hypercortisolism. J Comput Assist Tomogr. 1991;15(5):773–9. [PubMed: 1653280]

14.

Aron DC, Findling JW, Fitzgerald PA, Brooks RM, Fisher FE, Forsham PH, et al. Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing's syndrome. Report of two cases and review of the literature. Am J Med. 1981;71(2):302–6. [PubMed: 6266251]

15.

Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab. 2005;90(8):4955–62. [PubMed: 15914534]

16.

Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab. 2006;91(2):371–7. [PubMed: 16303835]

17.

Aniszewski JP, Young WF Jr, Thompson GB, Grant CS, van Heerden JA. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. World J Surg. 2001;25(7):934–40. [PubMed: 11572035]

18.

Drouin J. 60 YEARS OF POMC: Transcriptional and epigenetic regulation of POMC gene expression. J Mol Endocrinol. 2016;56(4):T99–T112. [PubMed: 26792828]

19.

Ye L, Li X, Kong X, Wang W, Bi Y, Hu L, et al. Hypomethylation in the promoter region of POMC gene correlates with ectopic overexpression in thymic carcinoids. J Endocrinol. 2005;185(2):337–43. [PubMed: 15845926]

20.

Newell-Price J, King P, Clark AJ. The CpG island promoter of the human proopiomelanocortin gene is methylated in nonexpressing normal tissue and tumors and represses expression. Mol Endocrinol. 2001;15(2):338–48. [PubMed: 11158338]

21.

Clark AJ, Lavender PM, Besser GM, Rees LH. Pro-opiomelanocortin mRNA size heterogeneity in ACTH-dependent Cushing's syndrome. J Mol Endocrinol. 1989;2(1):3–9. [PubMed: 2765113]

22.

Stewart MF, Crosby SR, Gibson S, Twentyman PR, White A. Small cell lung cancer cell lines secrete predominantly ACTH precursor peptides not ACTH. Br J Cancer. 1989;60(1):20–4. [PMC free article: PMC2247354] [PubMed: 2553086]

23.

Oliver RL, Davis JR, White A. Characterisation of ACTH related peptides in ectopic Cushing's syndrome. Pituitary. 2003;6(3):119–26. [PubMed: 14971736]

24.

Shahani S, Nudelman RJ, Nalini R, Kim HS, Samson SL. Ectopic corticotropin-releasing hormone (CRH) syndrome from metastatic small cell carcinoma: a case report and review of the literature. Diagn Pathol. 2010;5:56. [PMC free article: PMC2942804] [PubMed: 20807418]

25.

Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab. 1999;84(2):440–8. [PubMed: 10022398]

26.

Findlay JC, Sheeler LR, Engeland WC, Aron DC. Familial adrenocorticotropin-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab. 1993;76(1):189–91. [PubMed: 8380604]

27.

Lacroix A, Bolte E, Tremblay J, Dupre J, Poitras P, Fournier H, et al. Gastric inhibitory polypeptide-dependent cortisol hypersecretion--a new cause of Cushing's syndrome. N Engl J Med. 1992;327(14):974–80. [PubMed: 1325608]

28.

Reznik Y, Allali-Zerah V, Chayvialle JA, Leroyer R, Leymarie P, Travert G, et al. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med. 1992;327(14):981–6. [PubMed: 1325609]

29.

Karapanou O, Vlassopoulou B, Tzanela M, Stratigou T, Tsatlidis V, Tsirona S, et al. Adrenocorticotropic hormone independent macronodular adrenal hyperplasia due to aberrant receptor expression: is medical treatment always an option? Endocr Pract. 2013;19(3):e77–82. [PubMed: 23425648]

30.

de Groot JW, Links TP, Themmen AP, Looijenga LH, de Krijger RR, van Koetsveld PM, et al. Aberrant expression of multiple hormone receptors in ACTH-independent macronodular adrenal hyperplasia causing Cushing's syndrome. Eur J Endocrinol. 2010;163(2):293–9. [PubMed: 20460422]

31.

Assie G, Libe R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med. 2013;369(22):2105–14. [PMC free article: PMC4727443] [PubMed: 24283224]

32.

Kirk JM, Brain CE, Carson DJ, Hyde JC, Grant DB. Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr. 1999;134(6):789–92. [PubMed: 10356155]

33.

Boyce AM. Fibrous Dysplasia. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000.

34.

Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325(24):1688–95. [PubMed: 1944469]

35.

Boston BA, Mandel S, LaFranchi S, Bliziotes M. Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia. J Clin Endocrinol Metab. 1994;79(3):890–3. [PubMed: 8077378]

36.

Travis WD, Tsokos M, Doppman JL, Nieman L, Chrousos GP, Cutler GB Jr, et al. Primary pigmented nodular adrenocortical disease. A light and electron microscopic study of eight cases. Am J Surg Pathol. 1989;13(11):921–30. [PubMed: 2679153]

37.

Kaltsas G, Kanakis G, Chrousos G. Carney Complex. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000.

38.

Kiefer FW, Winhofer Y, Iacovazzo D, Korbonits M, Wolfsberger S, Knosp E, et al. PRKAR1A mutation causing pituitary-dependent Cushing disease in a patient with Carney complex. Eur J Endocrinol. 2017;177(2):K7–K12. [PubMed: 28522647]

39.

Hernandez-Ramirez LC, Tatsi C, Lodish MB, Faucz FR, Pankratz N, Chittiboina P, et al. Corticotropinoma as a Component of Carney Complex. J Endocr Soc. 2017;1(7):918–25. [PMC free article: PMC5686778] [PubMed: 29264542]

40.

Stratakis CA, Boikos SA. Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias. Nat Clin Pract Endocrinol Metab. 2007;3(11):748–57. [PubMed: 17955016]

41.

Swords FM, Baig A, Malchoff DM, Malchoff CD, Thorner MO, King PJ, et al. Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity. Mol Endocrinol. 2002;16(12):2746–53. [PubMed: 12456795]

42.

Lalau JD, Vieau D, Tenenbaum F, Westeel PF, Mesmacque A, Lenne F, et al. A case of pseudo-Nelson's syndrome: cure of ACTH hypersecretion by removal of a bronchial carcinoid tumor responsible for Cushing's syndrome. J Endocrinol Invest. 1990;13(6):531–7. [PubMed: 2175323]

43.

Contreras P, Altieri E, Liberman C, Gac A, Rojas A, Ibarra A, et al. Adrenal rest tumor of the liver causing Cushing's syndrome: treatment with ketoconazole preceding an apparent surgical cure. J Clin Endocrinol Metab. 1985;60(1):21–8. [PubMed: 3964792]

44.

Marieb NJ, Spangler S, Kashgarian M, Heimann A, Schwartz ML, Schwartz PE. Cushing's syndrome secondary to ectopic cortisol production by an ovarian carcinoma. J Clin Endocrinol Metab. 1983;57(4):737–40. [PubMed: 6309883]

45.

Nicolaides NC, Pavlaki AN, Maria Alexandra MA, Chrousos GP. Glucocorticoid Therapy and Adrenal Suppression. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000. [PubMed: 25905379]

46.

Ross EJ, Linch DC. Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet. 1982;2(8299):646–9. [PubMed: 6125785]

47.

Pecori Giraldi F, Moro M, Cavagnini F. Study Group on the Hypothalamo-Pituitary-Adrenal Axis of the Italian Society of E. Gender-related differences in the presentation and course of Cushing's disease. J Clin Endocrinol Metab. 2003;88(4):1554–8. [PubMed: 12679438]

48.

Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011;165(3):383–92. [PubMed: 21715416]

49.

Puglisi S, Perotti P, Pia A, Reimondo G, Terzolo M. Adrenocortical Carcinoma with Hypercortisolism. Endocrinol Metab Clin North Am. 2018;47(2):395–407. [PubMed: 29754640]

50.

Chatzellis E, Kaltsas G. Adrenal Incidentalomas. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000.

51.

Wajchenberg BL, Bosco A, Marone MM, Levin S, Rocha M, Lerario AC, et al. Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. J Clin Endocrinol Metab. 1995;80(9):2791–4. [PubMed: 7673425]

52.

Koch CA, Doppman JL, Watson JC, Patronas NJ, Nieman LK. Spinal epidural lipomatosis in a patient with the ectopic corticotropin syndrome. N Engl J Med. 1999;341(18):1399–400. [PubMed: 10577094]

53.

Panzer SW, Patrinely JR, Wilson HK. Exophthalmos and iatrogenic Cushing's syndrome. Ophthalmic Plast Reconstr Surg. 1994;10(4):278–82. [PubMed: 7865451]

54.

Baid SK, Rubino D, Sinaii N, Ramsey S, Frank A, Nieman LK. Specificity of screening tests for Cushing's syndrome in an overweight and obese population. J Clin Endocrinol Metab. 2009;94(10):3857–64. [PMC free article: PMC2758724] [PubMed: 19602562]

55.

Kaltsas G, Manetti L, Grossman AB. Osteoporosis in Cushing's syndrome. Front Horm Res. 2002;30:60–72. [PubMed: 11892271]

56.

Ilias I, Zoumakis E, Ghayee H. An Overview of Glucocorticoid Induced Osteoporosis. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000. [PubMed: 25905202]

57.

Canalis E. Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab. 1996;81(10):3441–7. [PubMed: 8855781]

58.

Felson DT, Anderson JJ. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet. 1987;1(8538):902–6. [PubMed: 2882300]

59.

Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J. Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. Eur J Endocrinol. 2006;154(1):109–18. [PubMed: 16381999]

60.

Toth M, Grossman A. Glucocorticoid-induced osteoporosis: lessons from Cushing's syndrome. Clin Endocrinol (Oxf). 2013;79(1):1–11. [PubMed: 23452135]

61.

Wajchenberg BL, Mendonca BB, Liberman B, Pereira MA, Carneiro PC, Wakamatsu A, et al. Ectopic adrenocorticotropic hormone syndrome. Endocr Rev. 1994;15(6):752–87. [PubMed: 7705280]

62.

Orth DN. Cushing's syndrome. N Engl J Med. 1995;332(12):791–803. [PubMed: 7862184]

63.

Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, Perry LA, Grossman AB, Besser GM, et al. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab. 1998;83(9):3083–8. [PubMed: 9745407]

64.

Luton JP, Thieblot P, Valcke JC, Mahoudeau JA, Bricaire H. Reversible gonadotropin deficiency in male Cushing's disease. J Clin Endocrinol Metab. 1977;45(3):488–95. [PubMed: 198424]

65.

Kaltsas GA, Korbonits M, Isidori AM, Webb JA, Trainer PJ, Monson JP, et al. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome? Clin Endocrinol (Oxf). 2000;53(4):493–500. [PubMed: 11012575]

66.

Giustina A, Bossoni S, Bussi AR, Pozzi A, Wehrenberg WB. Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing's disease. Endocr Res. 1993;19(1):47–56. [PubMed: 7681769]

67.

Bartalena L, Martino E, Petrini L, Velluzzi F, Loviselli A, Grasso L, et al. The nocturnal serum thyrotropin surge is abolished in patients with adrenocorticotropin (ACTH)-dependent or ACTH-independent Cushing's syndrome. J Clin Endocrinol Metab. 1991;72(6):1195–9. [PubMed: 1851180]

68.

Colao A, Pivonello R, Faggiano A, Filippella M, Ferone D, Di Somma C, et al. Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol (Oxf). 2000;53(1):13–9. [PubMed: 10931076]

69.

Niepomniszcze H, Pitoia F, Katz SB, Chervin R, Bruno OD. Primary thyroid disorders in endogenous Cushing's syndrome. Eur J Endocrinol. 2002;147(3):305–11. [PubMed: 12213667]

70.

Stewart PM, Krozowski ZS. 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm. 1999;57:249–324. [PubMed: 10232052]

71.

Christy NP, Laragh JH. Pathogenesis of hypokalemic alkalosis in Cushing's syndrome. N Engl J Med. 1961;265:1083–8. [PubMed: 13879332]

72.

Biering H, Knappe G, Gerl H, Lochs H. Acta Med Austriaca. 2000;27(1):27–31. [Prevalence of diabetes in acromegaly and Cushing syndrome] [PubMed: 10812460]

73.

Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611–29. [PubMed: 27177728]

74.

Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88(12):5593–602. [PubMed: 14671138]

75.

Feingold KR. Atypical Forms of Diabetes. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000.

76.

Catargi B, Rigalleau V, Poussin A, Ronci-Chaix N, Bex V, Vergnot V, et al. Occult Cushing's syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003;88(12):5808–13. [PubMed: 14671173]

77.

Krarup T, Krarup T, Hagen C. Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing's syndrome? Diabetes Metab Res Rev. 2012;28(3):219–27. [PubMed: 22162117]

78.

Mullan K, Black N, Thiraviaraj A, Bell PM, Burgess C, Hunter SJ, et al. Is there value in routine screening for Cushing's syndrome in patients with diabetes? J Clin Endocrinol Metab. 2010;95(5):2262–5. [PubMed: 20237165]

79.

Newsome S, Chen K, Hoang J, Wilson JD, Potter JM, Hickman PE. Cushing's syndrome in a clinic population with diabetes. Intern Med J. 2008;38(3):178–82. [PubMed: 17645502]

80.

Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526–40. [PMC free article: PMC2386281] [PubMed: 18334580]

81.

Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C, Torlontano M, Coletti F, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab. 2010;95(6):2736–45. [PubMed: 20375210]

82.

Feingold KR, Brinton EA, Grunfeld C. The Effect of Endocrine Disorders on Lipids and Lipoproteins. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000. [PubMed: 28121116]

83.

Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M. Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology. 2010;92 Suppl 1:86–90. [PubMed: 20829625]

84.

Neary NM, Booker OJ, Abel BS, Matta JR, Muldoon N, Sinaii N, et al. Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography. J Clin Endocrinol Metab. 2013;98(5):2045–52. [PMC free article: PMC3644598] [PubMed: 23559084]

85.

Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci. 2002;970:134–44. [PubMed: 12381548]

86.

De Leo M, Pivonello R, Auriemma RS, Cozzolino A, Vitale P, Simeoli C, et al. Cardiovascular disease in Cushing's syndrome: heart versus vasculature. Neuroendocrinology. 2010;92 Suppl 1:50–4. [PubMed: 20829618]

87.

Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84(8):2664–72. [PubMed: 10443657]

88.

Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003;88(6):2527–33. [PubMed: 12788849]

89.

Jyotsna VP, Naseer A, Sreenivas V, Gupta N, Deepak KK. Effect of Cushing's syndrome - Endogenous hypercortisolemia on cardiovascular autonomic functions. Auton Neurosci. 2011;160(1-2):99–102. [PubMed: 21177144]

90.

Alexandraki KI, Kaltsas GA, Vouliotis AI, Papaioannou TG, Trisk L, Zilos A, et al. Specific electrocardiographic features associated with Cushing's disease. Clin Endocrinol (Oxf). 2011;74(5):558–64. [PubMed: 21470280]

91.

Trementino L, Arnaldi G, Appolloni G, Daidone V, Scaroni C, Casonato A, et al. Coagulopathy in Cushing's syndrome. Neuroendocrinology. 2010;92 Suppl 1:55–9. [PubMed: 20829619]

92.

Stuijver DJ, van Zaane B, Feelders RA, Debeij J, Cannegieter SC, Hermus AR, et al. Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. J Clin Endocrinol Metab. 2011;96(11):3525–32. [PubMed: 21880802]

93.

Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab. 2002;87(8):3662–6. [PubMed: 12161492]

94.

van der Pas R, Leebeek FW, Hofland LJ, de Herder WW, Feelders RA. Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf). 2013;78(4):481–8. [PubMed: 23134530]

95.

Kelly W. Exophthalmos in Cushing's syndrome. Clin Endocrinol (Oxf). 1996;45(2):167–70. [PubMed: 8881448]

96.

Kelly WF. Psychiatric aspects of Cushing's syndrome. QJM. 1996;89(7):543–51. [PubMed: 8759496]

97.

Santos A, Resmini E, Pascual JC, Crespo I, Webb SM. Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management. Drugs. 2017;77(8):829–42. [PubMed: 28393326]

98.

Forget H, Lacroix A, Somma M, Cohen H. Cognitive decline in patients with Cushing's syndrome. J Int Neuropsychol Soc. 2000;6(1):20–9. [PubMed: 10761364]

99.

Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. Biol Psychiatry. 1992;32(9):756–65. [PubMed: 1450290]

100.

Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270(5234):283–6. [PubMed: 7569975]

101.

Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab. 2000;85(1):42–7. [PubMed: 10634361]

102.

Meinardi JR, Wolffenbuttel BH, Dullaart RP. Cyclic Cushing's syndrome: a clinical challenge. Eur J Endocrinol. 2007;157(3):245–54. [PubMed: 17766705]

103.

Valassi E, Franz H, Brue T, Feelders RA, Netea-Maier R, Tsagarakis S, et al. Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. Eur J Endocrinol. 2017;176(5):613–24. [PubMed: 28377460]

104.

Carroll T, Raff H, Findling JW. Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta-analysis. Endocr Pract. 2009;15(4):335–42. [PubMed: 19502211]

105.

Liu H, Bravata DM, Cabaccan J, Raff H, Ryzen E. Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin Endocrinol (Oxf). 2005;63(6):642–9. [PubMed: 16343098]

106.

Raff H. Utility of salivary cortisol measurements in Cushing's syndrome and adrenal insufficiency. J Clin Endocrinol Metab. 2009;94(10):3647–55. [PubMed: 19602555]

107.

Masserini B, Morelli V, Bergamaschi S, Ermetici F, Eller-Vainicher C, Barbieri AM, et al. The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. Eur J Endocrinol. 2009;160(1):87–92. [PubMed: 18835977]

108.

Castro M, Elias PC, Quidute AR, Halah FP, Moreira AC. Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab. 1999;84(3):878–82. [PubMed: 10084565]

109.

Nunes ML, Vattaut S, Corcuff JB, Rault A, Loiseau H, Gatta B, et al. Late-night salivary cortisol for diagnosis of overt and subclinical Cushing's syndrome in hospitalized and ambulatory patients. J Clin Endocrinol Metab. 2009;94(2):456–62. [PubMed: 19001518]

110.

Carrasco CA, Coste J, Guignat L, Groussin L, Dugue MA, Gaillard S, et al. Midnight salivary cortisol determination for assessing the outcome of transsphenoidal surgery in Cushing's disease. J Clin Endocrinol Metab. 2008;93(12):4728–34. [PubMed: 18728161]

111.

Doherty GM, Nieman LK, Cutler GB Jr, Chrousos GP, Norton JA. Time to recovery of the hypothalamic-pituitary-adrenal axis after curative resection of adrenal tumors in patients with Cushing's syndrome. Surgery. 1990;108(6):1085–90. [PubMed: 2247834]

112.

Galm BP, Qiao N, Klibanski A, Biller BMK, Tritos NA. Accuracy of Laboratory Tests for the Diagnosis of Cushing Syndrome. J Clin Endocrinol Metab. 2020;105(6) [PubMed: 32133504]

113.

Corcuff JB, Tabarin A, Rashedi M, Duclos M, Roger P, Ducassou D. Overnight urinary free cortisol determination: a screening test for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf). 1998;48(4):503–8. [PubMed: 9640418]

114.

Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA. 1993;269(17):2232–8. [PubMed: 8386285]

115.

Carroll BJ, Curtis GC, Davies BM, Mendels J, Sugerman AA. Urinary free cortisol excretion in depression. Psychol Med. 1976;6(1):43–50. [PubMed: 935296]

116.

Vila R, Granada ML, Guitierrez RM, Fernandez-Lopez JA, Remesar X, Formiguera X, et al. Urinary free cortisol excretion pattern in morbid obese women. Endocr Res. 2001;27(1-2):261–8. [PubMed: 11428718]

117.

Lin CL, Wu TJ, Machacek DA, Jiang NS, Kao PC. Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab. 1997;82(1):151–5. [PubMed: 8989250]

118.

Meikle AW, Findling J, Kushnir MM, Rockwood AL, Nelson GJ, Terry AH. Pseudo-Cushing syndrome caused by fenofibrate interference with urinary cortisol assayed by high-performance liquid chromatography. J Clin Endocrinol Metab. 2003;88(8):3521–4. [PubMed: 12915630]

119.

Liddle GW. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab. 1960;20:1539–60. [PubMed: 13761950]

120.

Kennedy L, Atkinson AB, Johnston H, Sheridan B, Hadden DR. Serum cortisol concentrations during low dose dexamethasone suppression test to screen for Cushing's syndrome. Br Med J (Clin Res Ed). 1984;289(6453):1188–91. [PMC free article: PMC1443333] [PubMed: 6437479]

121.

Nugent CA, Nichols T, Tyler FH. Diagnosis of Cushing's Syndrome; Single Dose Dexamethasone Suppression Test. Arch Intern Med. 1965;116:172–6. [PubMed: 14315650]

122.

McHardy-Young S, Harris PW, Lessof MH, Lyne C. Singledose dexamethasone suppression test for Cushing's Syndrome. Br Med J. 1967;2(5554):740–4. [PMC free article: PMC1841769] [PubMed: 6025982]

123.

Shimizu N, Yoshida H. Studies on the "low dose" suppressible Cushing's disease. Endocrinol Jpn. 1976;23(6):479–84. [PubMed: 1022523]

124.

Crapo L. Cushing's syndrome: a review of diagnostic tests. Metabolism. 1979;28(9):955–77. [PubMed: 225638]

125.

Odagiri E, Demura R, Demura H, Suda T, Ishiwatari N, Abe Y, et al. The changes in plasma cortisol and urinary free cortisol by an overnight dexamethasone suppression test in patients with Cushing's disease. Endocrinol Jpn. 1988;35(6):795–802. [PubMed: 3250858]

126.

Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B. Evidence for the low dose dexamethasone suppression test to screen for Cushing's syndrome--recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem. 1997;34(Pt 3):222–9. [PubMed: 9158818]

127.

Doppman JL, Chang R, Oldfield EH, Chrousos G, Stratakis CA, Nieman LK. The hypoplastic inferior petrosal sinus: a potential source of false-negative results in petrosal sampling for Cushing's disease. J Clin Endocrinol Metab. 1999;84(2):533–40. [PubMed: 10022412]

128.

Bernini GP, Argenio GF, Cerri F, Franchi F. Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions. J Endocrinol Invest. 1994;17(10):799–804. [PubMed: 7699214]

129.

Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf). 1995;43(5):545–50. [PubMed: 8548938]

130.

Trainer PJ, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf). 1991;34(4):317–30. [PubMed: 1879062]

131.

Papanicolaou DA, Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. A single midnight serum cortisol measurement distinguishes Cushing's syndrome from pseudo-Cushing states. J Clin Endocrinol Metab. 1998;83(4):1163–7. [PubMed: 9543134]

132.

Nieman L. Editorial: The dexamethasone-suppressed corticotropin-releasing hormone test for the diagnosis of Cushing's syndrome: what have we learned in 14 years? J Clin Endocrinol Metab. 2007;92(8):2876–8. [PubMed: 17682087]

133.

Van Cauter E, Refetoff S. Evidence for two subtypes of Cushing's disease based on the analysis of episodic cortisol secretion. N Engl J Med. 1985;312(21):1343–9. [PubMed: 3873008]

134.

Lytras N, Grossman A, Perry L, Tomlin S, Wass JA, Coy DH, et al. Corticotrophin releasing factor: responses in normal subjects and patients with disorders of the hypothalamus and pituitary. Clin Endocrinol (Oxf). 1984;20(1):71–84. [PubMed: 6319053]

135.

Greene LW, Geer EB, Page-Wilson G, Findling JW, Raff H. Assay-Specific Spurious ACTH Results Lead to Misdiagnosis, Unnecessary Testing, and Surgical Misadventure-A Case Series. J Endocr Soc. 2019;3(4):763–72. [PMC free article: PMC6446888] [PubMed: 30963134]

136.

Fig LM, Gross MD, Shapiro B, Ehrmann DA, Freitas JE, Schteingart DE, et al. Adrenal localization in the adrenocorticotropic hormone-independent Cushing syndrome. Ann Intern Med. 1988;109(7):547–53. [PubMed: 3421563]

137.

Wagner-Bartak NA, Baiomy A, Habra MA, Mukhi SV, Morani AC, Korivi BR, et al. Cushing Syndrome: Diagnostic Workup and Imaging Features, With Clinical and Pathologic Correlation. AJR Am J Roentgenol. 2017;209(1):19–32. [PubMed: 28639924]

138.

Doppman JL, Miller DL, Dwyer AJ, Loughlin T, Nieman L, Cutler GB, et al. Macronodular adrenal hyperplasia in Cushing disease. Radiology. 1988;166(2):347–52. [PubMed: 2827231]

139.

Blake MA, Kalra MK, Sweeney AT, Lucey BC, Maher MM, Sahani DV, et al. Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology. 2006;238(2):578–85. [PubMed: 16371582]

140.

Wei J, Li S, Liu Q, Zhu Y, Wu N, Tang Y, et al. ACTH-independent Cushing's syndrome with bilateral cortisol-secreting adrenal adenomas: a case report and review of literatures. BMC Endocr Disord. 2018;18(1):22. [PMC free article: PMC5913873] [PubMed: 29685132]

141.

Doppman JL, Travis WD, Nieman L, Miller DL, Chrousos GP, Gomez MT, et al. Cushing syndrome due to primary pigmented nodular adrenocortical disease: findings at CT and MR imaging. Radiology. 1989;172(2):415–20. [PubMed: 2748822]

142.

Malchoff CD, Rosa J, DeBold CR, Kozol RA, Ramsby GR, Page DL, et al. Adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia: an unusual cause of Cushing's syndrome. J Clin Endocrinol Metab. 1989;68(4):855–60. [PubMed: 2537845]

143.

Sohaib SA, Hanson JA, Newell-Price JD, Trainer PJ, Monson JP, Grossman AB, et al. CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing's syndrome. AJR Am J Roentgenol. 1999;172(4):997–1002. [PubMed: 10587135]

144.

Newell-Price J, Morris DG, Drake WM, Korbonits M, Monson JP, Besser GM, et al. Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab. 2002;87(4):1640–5. [PubMed: 11932295]

145.

Howlett TA, Drury PL, Perry L, Doniach I, Rees LH, Besser GM. Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol (Oxf). 1986;24(6):699–713. [PubMed: 3024870]

146.

Findling JW, Kehoe ME, Shaker JL, Raff H. Routine inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin (ACTH)-dependent Cushing's syndrome: early recognition of the occult ectopic ACTH syndrome. J Clin Endocrinol Metab. 1991;73(2):408–13. [PubMed: 1649842]

147.

Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med. 1991;325(13):897–905. [PubMed: 1652686]

148.

Kaltsas GA, Giannulis MG, Newell-Price JD, Dacie JE, Thakkar C, Afshar F, et al. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab. 1999;84(2):487–92. [PubMed: 10022405]

149.

Colao A, Faggiano A, Pivonello R, Pecori Giraldi F, Cavagnini F, Lombardi G, et al. Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. Eur J Endocrinol. 2001;144(5):499–507. [PubMed: 11331216]

150.

Swearingen B, Katznelson L, Miller K, Grinspoon S, Waltman A, Dorer DJ, et al. Diagnostic errors after inferior petrosal sinus sampling. J Clin Endocrinol Metab. 2004;89(8):3752–63. [PubMed: 15292301]

151.

Wang H, Ba Y, Xing Q, Cai RC. Differential diagnostic value of bilateral inferior Petrosal sinus sampling (BIPSS) in ACTH-dependent Cushing syndrome: a systematic review and Meta-analysis. BMC Endocr Disord. 2020;20(1):143. [PMC free article: PMC7499975] [PubMed: 32943040]

152.

Yamamoto Y, Davis DH, Nippoldt TB, Young WF Jr, Huston J 3rd, Parisi JE. False-positive inferior petrosal sinus sampling in the diagnosis of Cushing's disease. Report of two cases. J Neurosurg. 1995;83(6):1087–91. [PubMed: 7490627]

153.

McCance DR, McIlrath E, McNeill A, Gordon DS, Hadden DR, Kennedy L, et al. Bilateral inferior petrosal sinus sampling as a routine procedure in ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf). 1989;30(2):157–66. [PubMed: 2558816]

154.

Machado MC, de Sa SV, Domenice S, Fragoso MC, Puglia P Jr, Pereira MA, et al. The role of desmopressin in bilateral and simultaneous inferior petrosal sinus sampling for differential diagnosis of ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf). 2007;66(1):136–42. [PubMed: 17201813]

155.

Miller DL, Doppman JL, Peterman SB, Nieman LK, Oldfield EH, Chang R. Neurologic complications of petrosal sinus sampling. Radiology. 1992;185(1):143–7. [PubMed: 1523298]

156.

Lefournier V, Gatta B, Martinie M, Vasdev A, Tabarin A, Bessou P, et al. One transient neurological complication (sixth nerve palsy) in 166 consecutive inferior petrosal sinus samplings for the etiological diagnosis of Cushing's syndrome. J Clin Endocrinol Metab. 1999;84(9):3401–2. [PubMed: 10487721]

157.

Rotman-Pikielny P, Patronas N, Papanicolaou DA. Pituitary apoplexy induced by corticotrophin-releasing hormone in a patient with Cushing's disease. Clin Endocrinol (Oxf). 2003;58(5):545–9. [PubMed: 12699434]

158.

Erickson D, Huston J 3rd, Young WF Jr, Carpenter PC, Wermers RA, Bonelli FS, et al. Internal jugular vein sampling in adrenocorticotropic hormone-dependent Cushing's syndrome: a comparison with inferior petrosal sinus sampling. Clin Endocrinol (Oxf). 2004;60(4):413–9. [PubMed: 15049954]

159.

Sharma ST, Raff H, Nieman LK. Prolactin as a marker of successful catheterization during IPSS in patients with ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab. 2011;96(12):3687–94. [PMC free article: PMC3232627] [PubMed: 22031511]

160.

Tabarin A, Greselle JF, San-Galli F, Leprat F, Caille JM, Latapie JL, et al. Usefulness of the corticotropin-releasing hormone test during bilateral inferior petrosal sinus sampling for the diagnosis of Cushing's disease. J Clin Endocrinol Metab. 1991;73(1):53–9. [PubMed: 1646218]

161.

Landolt AM, Schubiger O, Maurer R, Girard J. The value of inferior petrosal sinus sampling in diagnosis and treatment of Cushing's disease. Clin Endocrinol (Oxf). 1994;40(4):485–92. [PubMed: 8187314]

162.

Lefournier V, Martinie M, Vasdev A, Bessou P, Passagia JG, Labat-Moleur F, et al. Accuracy of bilateral inferior petrosal or cavernous sinuses sampling in predicting the lateralization of Cushing's disease pituitary microadenoma: influence of catheter position and anatomy of venous drainage. J Clin Endocrinol Metab. 2003;88(1):196–203. [PubMed: 12519852]

163.

Wind JJ, Lonser RR, Nieman LK, DeVroom HL, Chang R, Oldfield EH. The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing's disease. J Clin Endocrinol Metab. 2013;98(6):2285–93. [PMC free article: PMC3667263] [PubMed: 23553862]

164.

Liu Z, Zhang X, Wang Z, You H, Li M, Feng F, et al. High positive predictive value of the combined pituitary dynamic enhanced MRI and high-dose dexamethasone suppression tests in the diagnosis of Cushing's disease bypassing bilateral inferior petrosal sinus sampling. Sci Rep. 2020;10(1):14694. [PMC free article: PMC7476924] [PubMed: 32895443]

165.

Lienhardt A, Grossman AB, Dacie JE, Evanson J, Huebner A, Afshar F, et al. Relative contributions of inferior petrosal sinus sampling and pituitary imaging in the investigation of children and adolescents with ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab. 2001;86(12):5711–4. [PubMed: 11739426]

166.

Morris DG, Grossman AB. Dynamic tests in the diagnosis and differential diagnosis of Cushing's syndrome. J Endocrinol Invest. 2003;26(7) Suppl:64–73. [PubMed: 14604068]

167.

Miller DL, Doppman JL, Nieman LK, Cutler GB Jr, Chrousos G, Loriaux DL, et al. Petrosal sinus sampling: discordant lateralization of ACTH-secreting pituitary microadenomas before and after stimulation with corticotropin-releasing hormone. Radiology. 1990;176(2):429–31. [PubMed: 2164235]

168.

Strott CA, Nugent CA, Tyler FH. Cushing's syndrome caused by bronchial adenomas. Am J Med. 1968;44(1):97–104. [PubMed: 4294885]

169.

Malchoff CD, Orth DN, Abboud C, Carney JA, Pairolero PC, Carey RM. Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. Am J Med. 1988;84(4):760–4. [PubMed: 2840823]

170.

Dichek HL, Nieman LK, Oldfield EH, Pass HI, Malley JD, Cutler GB Jr. A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab. 1994;78(2):418–22. [PubMed: 8106630]

171.

Nieman LK, Chrousos GP, Oldfield EH, Avgerinos PC, Cutler GB Jr, Loriaux DL. The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome. Ann Intern Med. 1986;105(6):862–7. [PubMed: 3022629]

172.

Grossman AB, Howlett TA, Perry L, Coy DH, Savage MO, Lavender P, et al. CRF in the differential diagnosis of Cushing's syndrome: a comparison with the dexamethasone suppression test. Clin Endocrinol (Oxf). 1988;29(2):167–78. [PubMed: 2854761]

173.

Tyrrell JB, Findling JW, Aron DC, Fitzgerald PA, Forsham PH. An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome. Ann Intern Med. 1986;104(2):180–6. [PubMed: 3004275]

174.

Isidori AM, Kaltsas GA, Mohammed S, Morris DG, Jenkins P, Chew SL, et al. Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab. 2003;88(11):5299–306. [PubMed: 14602765]

175.

Trainer PJ, Faria M, Newell-Price J, Browne P, Kopelman P, Coy DH, et al. A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis. J Clin Endocrinol Metab. 1995;80(2):412–7. [PubMed: 7852498]

176.

Trainer PJ, Woods RJ, Korbonits M, Popovic V, Stewart PM, Lowry PJ, et al. The pathophysiology of circulating corticotropin-releasing hormone-binding protein levels in the human. J Clin Endocrinol Metab. 1998;83(5):1611–4. [PubMed: 9589664]

177.

Nieman LK, Oldfield EH, Wesley R, Chrousos GP, Loriaux DL, Cutler GB Jr. A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab. 1993;77(5):1308–12. [PubMed: 8077325]

178.

Pecori Giraldi F, Invitti C, Cavagnini F., Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-pituitary-adrenal a. The corticotropin-releasing hormone test in the diagnosis of ACTH-dependent Cushing's syndrome: a reappraisal. Clin Endocrinol (Oxf). 2001;54(5):601–7. [PubMed: 11380490]

179.

Hermus AR, Pieters GF, Pesman GJ, Smals AG, Benraad TJ, Kloppenborg PW. The corticotropin-releasing-hormone test versus the high-dose dexamethasone test in the differential diagnosis of Cushing's syndrome. Lancet. 1986;2(8506):540–4. [PubMed: 2875282]

180.

Woo YS, Isidori AM, Wat WZ, Kaltsas GA, Afshar F, Sabin I, et al. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab. 2005;90(8):4963–9. [PubMed: 15886242]

181.

Korbonits M, Kaltsas G, Perry LA, Putignano P, Grossman AB, Besser GM, et al. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab. 1999;84(7):2489–95. [PubMed: 10404825]

182.

Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG, et al. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86(2):881–7. [PubMed: 11158061]

183.

Tabarin A, San Galli F, Dezou S, Leprat F, Corcuff JB, Latapie JL, et al. The corticotropin-releasing factor test in the differential diagnosis of Cushing's syndrome: a comparison with the lysine-vasopressin test. Acta Endocrinol (Copenh). 1990;123(3):331–8. [PubMed: 2239082]

184.

Malerbi DA, Mendonca BB, Liberman B, Toledo SP, Corradini MC, Cunha-Neto MB, et al. The desmopressin stimulation test in the differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf). 1993;38(5):463–72. [PubMed: 8330442]

185.

Ghigo E, Arvat E, Ramunni J, Colao A, Gianotti L, Deghenghi R, et al. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab. 1997;82(8):2439–44. [PubMed: 9253314]

186.

Newell-Price J, Perry L, Medbak S, Monson J, Savage M, Besser M, et al. A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab. 1997;82(1):176–81. [PubMed: 8989255]

187.

Tsagarakis S, Tsigos C, Vasiliou V, Tsiotra P, Kaskarelis J, Sotiropoulou C, et al. The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion. J Clin Endocrinol Metab. 2002;87(4):1646–53. [PubMed: 11932296]

188.

Korbonits M, Jacobs RA, Aylwin SJ, Burrin JM, Dahia PL, Monson JP, et al. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors. J Clin Endocrinol Metab. 1998;83(10):3624–30. [PubMed: 9768675]

189.

Evanson J. Radiology of the Pituitary. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000.

190.

Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med. 1994;120(10):817–20. [PubMed: 8154641]

191.

Patronas N, Bulakbasi N, Stratakis CA, Lafferty A, Oldfield EH, Doppman J, et al. Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J Clin Endocrinol Metab. 2003;88(4):1565–9. [PubMed: 12679440]

192.

Tabarin A, Laurent F, Catargi B, Olivier-Puel F, Lescene R, Berge J, et al. Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing's disease. Clin Endocrinol (Oxf). 1998;49(3):293–300. [PubMed: 9861318]

193.

Findling JW, Doppman JL. Biochemical and radiologic diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am. 1994;23(3):511–37. [PubMed: 7805651]

194.

Chatain GP, Patronas N, Smirniotopoulos JG, Piazza M, Benzo S, Ray-Chaudhury A, et al. Potential utility of FLAIR in MRI-negative Cushing's disease. J Neurosurg. 2018;129(3):620–8. [PMC free article: PMC6398169] [PubMed: 29027863]

195.

Escourolle H, Abecassis JP, Bertagna X, Guilhaume B, Pariente D, Derome P, et al. Comparison of computerized tomography and magnetic resonance imaging for the examination of the pituitary gland in patients with Cushing's disease. Clin Endocrinol (Oxf). 1993;39(3):307–13. [PubMed: 8222293]

196.

de Herder WW, Uitterlinden P, Pieterman H, Tanghe HL, Kwekkeboom DJ, Pols HA, et al. Pituitary tumour localization in patients with Cushing's disease by magnetic resonance imaging. Is there a place for petrosal sinus sampling? Clin Endocrinol (Oxf). 1994;40(1):87–92. [PubMed: 8306486]

197.

Buchfelder M, Nistor R, Fahlbusch R, Huk WJ. The accuracy of CT and MR evaluation of the sella turcica for detection of adrenocorticotropic hormone-secreting adenomas in Cushing disease. AJNR Am J Neuroradiol. 1993;14(5):1183–90. [PMC free article: PMC8332751] [PubMed: 8237701]

198.

Doppman JL, Pass HI, Nieman LK, Findling JW, Dwyer AJ, Feuerstein IM, et al. Detection of ACTH-producing bronchial carcinoid tumors: MR imaging vs CT. AJR Am J Roentgenol. 1991;156(1):39–43. [PubMed: 1845787]

199.

de Herder WW, Lamberts SW. Tumor localization--the ectopic ACTH syndrome. J Clin Endocrinol Metab. 1999;84(4):1184–5. [PubMed: 10199750]

200.

Tabarin A, Valli N, Chanson P, Bachelot Y, Rohmer V, Bex-Bachellerie V, et al. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab. 1999;84(4):1193–202. [PubMed: 10199752]

201.

Torpy DJ, Chen CC, Mullen N, Doppman JL, Carrasquillo JA, Chrousos GP, et al. Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab. 1999;84(4):1186–92. [PubMed: 10199751]

202.

Kumar J, Spring M, Carroll PV, Barrington SF, Powrie JK. 18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clin Endocrinol (Oxf). 2006;64(4):371–4. [PubMed: 16584507]

203.

Pacak K, Ilias I, Chen CC, Carrasquillo JA, Whatley M, Nieman LK. The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. J Clin Endocrinol Metab. 2004;89(5):2214–21. [PubMed: 15126544]

204.

Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588–601. [PubMed: 28547177]

205.

Santhanam P, Taieb D, Giovanella L, Treglia G. PET imaging in ectopic Cushing syndrome: a systematic review. Endocrine. 2015;50(2):297–305. [PubMed: 26206753]

206.

Treglia G, Giovanella L, Lococo F. Evolving role of PET/CT with different tracers in the evaluation of pulmonary neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41(5):853–5. [PubMed: 24557593]

207.

Isidori AM, Minnetti M, Sbardella E, Graziadio C, Grossman AB. Mechanisms in endocrinology: The spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur J Endocrinol. 2015;173(3):R101–13. [PubMed: 25987566]

208.

Jane JA, Jr., Catalino MP, Laws ER, Jr. Surgical Treatment of Pituitary Adenomas. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000.

209.

Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93(7):2454–62. [PMC free article: PMC3214276] [PubMed: 18413427]

210.

Lamberts SW, van der Lely AJ, de Herder WW. Transsphenoidal selective adenomectomy is the treatment of choice in patients with Cushing's disease. Considerations concerning preoperative medical treatment and the long-term follow-up. J Clin Endocrinol Metab. 1995;80(11):3111–3. [PubMed: 7593410]

211.

Netea-Maier RT, van Lindert EJ, den Heijer M, van der Eerden A, Pieters GF, Sweep CG, et al. Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing's disease. Eur J Endocrinol. 2006;154(5):675–84. [PubMed: 16645014]

212.

Wagenmakers MA, Netea-Maier RT, van Lindert EJ, Timmers HJ, Grotenhuis JA, Hermus AR. Repeated transsphenoidal pituitary surgery (TS) via the endoscopic technique: a good therapeutic option for recurrent or persistent Cushing's disease (CD). Clin Endocrinol (Oxf). 2009;70(2):274–80. [PubMed: 18616702]

213.

Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf). 2005;63(5):549–59. [PubMed: 16268808]

214.

Broersen LHA, Biermasz NR, van Furth WR, de Vries F, Verstegen MJT, Dekkers OM, et al. Endoscopic vs. microscopic transsphenoidal surgery for Cushing's disease: a systematic review and meta-analysis. Pituitary. 2018;21(5):524–34. [PMC free article: PMC6132967] [PubMed: 29767319]

215.

Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab. 1995;80(11):3114–20. [PubMed: 7593411]

216.

Blevins LS Jr, Christy JH, Khajavi M, Tindall GT. Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab. 1998;83(1):63–7. [PubMed: 9435417]

217.

Hughes NR, Lissett CA, Shalet SM. Growth hormone status following treatment for Cushing's syndrome. Clin Endocrinol (Oxf). 1999;51(1):61–6. [PubMed: 10468966]

218.

Kelly DF. Transsphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's Syndrome. Neurosurg Focus. 2007;23(3):E5. [PubMed: 17961026]

219.

Yamada S, Inoshita N, Fukuhara N, Yamaguchi-Okada M, Nishioka H, Takeshita A, et al. Therapeutic outcomes in patients undergoing surgery after diagnosis of Cushing's disease: A single-center study. Endocr J. 2015;62(12):1115–25. [PubMed: 26477323]

220.

Braun LT, Rubinstein G, Zopp S, Vogel F, Schmid-Tannwald C, Escudero MP, et al. Recurrence after pituitary surgery in adult Cushing's disease: a systematic review on diagnosis and treatment. Endocrine. 2020;70(2):218–31. [PMC free article: PMC7396205] [PubMed: 32743767]

221.

Bakiri F, Tatai S, Aouali R, Semrouni M, Derome P, Chitour F, et al. Treatment of Cushing's disease by transsphenoidal, pituitary microsurgery: prognosis factors and long-term follow-up. J Endocrinol Invest. 1996;19(9):572–80. [PubMed: 8957739]

222.

Prevedello DM, Pouratian N, Sherman J, Jane JA Jr, Vance ML, Lopes MB, et al. Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J Neurosurg. 2008;109(4):751–9. [PubMed: 18826366]

223.

Wilson CB, Mindermann T, Tyrrell JB. Extrasellar, intracavernous sinus adrenocorticotropin-releasing adenoma causing Cushing's disease. J Clin Endocrinol Metab. 1995;80(6):1774–7. [PubMed: 7775621]

224.

Weil RJ, Vortmeyer AO, Nieman LK, Devroom HL, Wanebo J, Oldfield EH. Surgical remission of pituitary adenomas confined to the neurohypophysis in Cushing's disease. J Clin Endocrinol Metab. 2006;91(7):2656–64. [PubMed: 16636117]

225.

Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg. 2002;96(2):195–208. [PubMed: 11838791]

226.

Sonino N, Zielezny M, Fava GA, Fallo F, Boscaro M. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab. 1996;81(7):2647–52. [PubMed: 8675592]

227.

Streeten DH, Anderson GH Jr, Dalakos T, Joachimpillai AD. Intermittent hypercortisolism: a disorder strikingly prevalent after hypophysial surgical procedures. Endocr Pract. 1997;3(3):123–9. [PubMed: 15251471]

228.

Kelly PA, Samandouras G, Grossman AB, Afshar F, Besser GM, Jenkins PJ. Neurosurgical treatment of Nelson's syndrome. J Clin Endocrinol Metab. 2002;87(12):5465–9. [PubMed: 12466338]

229.

McCance DR, Besser M, Atkinson AB. Assessment of cure after transsphenoidal surgery for Cushing's disease. Clin Endocrinol (Oxf). 1996;44(1):1–6. [PubMed: 8706280]

230.

Estrada J, Garcia-Uria J, Lamas C, Alfaro J, Lucas T, Diez S, et al. The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 2001;86(12):5695–9. [PubMed: 11739423]

231.

Newell-Price J. Transsphenoidal surgery for Cushing's disease: defining cure and following outcome. Clin Endocrinol (Oxf). 2002;56(1):19–21. [PubMed: 11849241]

232.

Yap LB, Turner HE, Adams CB, Wass JA. Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit. Clin Endocrinol (Oxf). 2002;56(1):25–31. [PubMed: 11849243]

233.

Pereira AM, van Aken MO, van Dulken H, Schutte PJ, Biermasz NR, Smit JW, et al. Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J Clin Endocrinol Metab. 2003;88(12):5858–64. [PubMed: 14671181]

234.

Esposito F, Dusick JR, Cohan P, Moftakhar P, McArthur D, Wang C, et al. Clinical review: Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 2006;91(1):7–13. [PubMed: 16234305]

235.

Lindsay JR, Oldfield EH, Stratakis CA, Nieman LK. The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing's disease after transsphenoidal surgery. J Clin Endocrinol Metab. 2011;96(7):2057–64. [PMC free article: PMC3135190] [PubMed: 21508126]

236.

Valassi E, Biller BM, Swearingen B, Pecori Giraldi F, Losa M, Mortini P, et al. Delayed remission after transsphenoidal surgery in patients with Cushing's disease. J Clin Endocrinol Metab. 2010;95(2):601–10. [PMC free article: PMC2840864] [PubMed: 20080848]

237.

Ram Z, Nieman LK, Cutler GB Jr, Chrousos GP, Doppman JL, Oldfield EH. Early repeat surgery for persistent Cushing's disease. J Neurosurg. 1994;80(1):37–45. [PubMed: 8271020]

238.

Locatelli M, Vance ML, Laws ER. Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 2005;90(9):5478–82. [PubMed: 15956075]

239.

Papanicolaou DA, Tsigos C, Oldfield EH, Chrousos GP. Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab. 1996;81(6):2303–6. [PubMed: 8964868]

240.

Leshin M. Acute adrenal insufficiency: recognition, management, and prevention. Urol Clin North Am. 1982;9(2):229–35. [PubMed: 6285575]

241.

Bangar V, Clayton RN. How reliable is the short synacthen test for the investigation of the hypothalamic-pituitary-adrenal axis? Eur J Endocrinol. 1998;139(6):580–3. [PubMed: 9916860]

242.

Stewart PM, Corrie J, Seckl JR, Edwards CR, Padfield PL. A rational approach for assessing the hypothalamo-pituitary-adrenal axis. Lancet. 1988;1(8596):1208–10. [PubMed: 2897016]

243.

Orme SM, Peacey SR, Barth JH, Belchetz PE. Comparison of tests of stress-released cortisol secretion in pituitary disease. Clin Endocrinol (Oxf). 1996;45(2):135–40. [PubMed: 8881444]

244.

Ammari F, Issa BG, Millward E, Scanion MF. A comparison between short ACTH and insulin stress tests for assessing hypothalamo-pituitary-adrenal function. Clin Endocrinol (Oxf). 1996;44(4):473–6. [PubMed: 8706316]

245.

Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, et al. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab. 2009;94(5):1548–54. [PMC free article: PMC2684472] [PubMed: 19223520]

246.

Timmers HJ, van Ginneken EM, Wesseling P, Sweep CG, Hermus AR. A patient with recurrent hypercortisolism after removal of an ACTH-secreting pituitary adenoma due to an adrenal macronodule. J Endocrinol Invest. 2006;29(10):934–9. [PubMed: 17185905]

247.

Olson BR, Rubino D, Gumowski J, Oldfield EH. Isolated hyponatremia after transsphenoidal pituitary surgery. J Clin Endocrinol Metab. 1995;80(1):85–91. [PubMed: 7829644]

248.

Nemergut EC, Zuo Z, Jane JA Jr, Laws ER Jr. Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. J Neurosurg. 2005;103(3):448–54. [PubMed: 16235676]

249.

Burke CW, Adams CB, Esiri MM, Morris C, Bevan JS. Transsphenoidal surgery for Cushing's disease: does what is removed determine the endocrine outcome? Clin Endocrinol (Oxf). 1990;33(4):525–37. [PubMed: 2171817]

250.

Ritzel K, Beuschlein F, Mickisch A, Osswald A, Schneider HJ, Schopohl J, et al. Clinical review: Outcome of bilateral adrenalectomy in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab. 2013;98(10):3939–48. [PubMed: 23956347]

251.

Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364–89. [PMC free article: PMC4880116] [PubMed: 26760044]

252.

Kemink L, Pieters G, Hermus A, Smals A, Kloppenborg P. Patient's age is a simple predictive factor for the development of Nelson's syndrome after total adrenalectomy for Cushing's disease. J Clin Endocrinol Metab. 1994;79(3):887–9. [PubMed: 8077377]

253.

Fountas A, Karavitaki N. Nelson's Syndrome: An Update. Endocrinol Metab Clin North Am. 2020;49(3):413–32. [PubMed: 32741480]

254.

Reincke M, Albani A., Stratakis C.A ., Buchfelder M., Heaney A.P., van Rossum E., Grossman A., Findling J., Brue T., Murakami M., Pecori Giraldi F., Losa M., Theodoropoulou M., Pivonello R., Detomas M., Daniele A., Sbiera S., Honegger J., Elenkova A., Zacharieva S., Lacroix A., Pérez‐Rivas L.G., Di Dalmazi G., Laws E.R., Newell-Price J.D., Gomez-Sanchez C.E., Karavitaki N., Bancos I., Rainey W.E., Chabre O., Valassi E., Assie G., Schopohl J., Rubinstein G., Ritzel K. Corticotroph tumor progression after bilateral adrenalectomy (Nelson’s syndrome: Systematic review and “Munich Expert Consensus. Eur J Endocrinol. 2020 [PMC free article: PMC8060870] [PubMed: 33444221]

255.

Fountas A, Lim ES, Drake WM, Powlson AS, Gurnell M, Martin NM, et al. Outcomes of Patients with Nelson's Syndrome after Primary Treatment: A Multicenter Study from 13 UK Pituitary Centers. J Clin Endocrinol Metab. 2020;105(5) [PubMed: 31735971]

256.

Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugue MA, et al. Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome. J Clin Endocrinol Metab. 2007;92(1):172–9. [PubMed: 17062771]

257.

Nagesser SK, van Seters AP, Kievit J, Hermans J, van Dulken H, Krans HM, et al. Treatment of pituitary-dependent Cushing's syndrome: long-term results of unilateral adrenalectomy followed by external pituitary irradiation compared to transsphenoidal pituitary surgery. Clin Endocrinol (Oxf). 2000;52(4):427–35. [PubMed: 10762285]

258.

Kosmin M, Fersht N. Radiotherapy for Pituitary Tumors. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000. [PubMed: 25905190]

259.

Devoe DJ, Miller WL, Conte FA, Kaplan SL, Grumbach MM, Rosenthal SM, et al. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 1997;82(10):3196–202. [PubMed: 9329338]

260.

Jennings AS, Liddle GW, Orth DN. Results of treating childhood Cushing's disease with pituitary irradiation. N Engl J Med. 1977;297(18):957–62. [PubMed: 909542]

261.

Nelson DH, Meakin JW, Thorn GW. ACTH-producing pituitary tumors following adrenalectomy for Cushing's syndrome. Ann Intern Med. 1960;52:560–9. [PubMed: 14426442]

262.

Howlett TA, Plowman PN, Wass JA, Rees LH, Jones AE, Besser GM. Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: long-term follow-up. Clin Endocrinol (Oxf). 1989;31(3):309–23. [PubMed: 2559823]

263.

Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med. 1997;336(3):172–7. [PubMed: 8988897]

264.

Minniti G, Osti M, Jaffrain-Rea ML, Esposito V, Cantore G, Maurizi Enrici R. Long-term follow-up results of postoperative radiation therapy for Cushing's disease. J Neurooncol. 2007;84(1):79–84. [PubMed: 17356896]

265.

Vance ML. Cushing's disease: radiation therapy. Pituitary. 2009;12(1):11–4. [PubMed: 18437577]

266.

Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B. Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol (Oxf). 2002;57(6):713–7. [PubMed: 12460319]

267.

Erfurth EM, Bulow B, Svahn-Tapper G, Norrving B, Odh K, Mikoczy Z, et al. Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J Clin Endocrinol Metab. 2002;87(11):4892–9. [PubMed: 12414846]

268.

Plowman PN. Pituitary adenoma radiotherapy-when, who and how? Clin Endocrinol (Oxf). 1999;51(3):265–71. [PubMed: 10469003]

269.

Mitsumori M, Shrieve DC, Alexander E 3rd, Kaiser UB, Richardson GE, Black PM, et al. Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys. 1998;42(3):573–80. [PubMed: 9806517]

270.

Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg. 1998;88(6):1002–8. [PubMed: 9609294]

271.

Thoren M, Hoybye C, Grenback E, Degerblad M, Rahn T, Hulting AL. The role of gamma knife radiosurgery in the management of pituitary adenomas. J Neurooncol. 2001;54(2):197–203. [PubMed: 11761436]

272.

Sheehan J, Lopes MB, Laws E. Pathological findings following radiosurgery of pituitary adenomas. Prog Neurol Surg. 2007;20:172–9. [PubMed: 17317985]

273.

Bunevicius A, Laws ER, Vance ML, Iuliano S, Sheehan J. Surgical and radiosurgical treatment strategies for Cushing's disease. J Neurooncol. 2019;145(3):403–13. [PubMed: 31677031]

274.

Swords FM, Monson JP, Besser GM, Chew SL, Drake WM, Grossman AB, et al. Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy. Eur J Endocrinol. 2009;161(6):819–28. [PubMed: 19773368]

275.

Petit JH, Biller BM, Yock TI, Swearingen B, Coen JJ, Chapman P, et al. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab. 2008;93(2):393–9. [PubMed: 18029460]

276.

Swords FM, Allan CA, Plowman PN, Sibtain A, Evanson J, Chew SL, et al. Stereotactic radiosurgery XVI: a treatment for previously irradiated pituitary adenomas. J Clin Endocrinol Metab. 2003;88(11):5334–40. [PubMed: 14602770]

277.

Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML. Gamma Knife surgery for Cushing's disease. J Neurosurg. 2007;106(6):980–7. [PubMed: 17564168]

278.

He J, Zhou J, Lu Z. Radiotherapy of ectopic ACTH syndrome due to thoracic carcinoids. Chin Med J (Engl). 1995;108(5):338–41. [PubMed: 7555233]

279.

Andres R, Mayordomo JI, Ramon y Cajal S, Tres A. Paraneoplastic Cushing's syndrome associated to locally advanced thymic carcinoid tumor. Tumori. 2002;88(1):65–7. [PubMed: 12004854]

280.

Miller CA, Ellison EC. Therapeutic alternatives in metastatic neuroendocrine tumors. Surg Oncol Clin N Am. 1998;7(4):863–79. [PubMed: 9735138]

281.

Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation. 1998;66(10):1307–12. [PubMed: 9846513]

282.

Tabarin A, Catargi B, Chanson P, Hieronimus S, Corcuff JB, Laurent F, et al. Pseudo-tumours of the thymus after correction of hypercortisolism in patients with ectopic ACTH syndrome: a report of five cases. Clin Endocrinol (Oxf). 1995;42(2):207–13. [PubMed: 7704966]

283.

Ur E, Grossman A. Corticotropin-releasing hormone in health and disease: an update. Acta Endocrinol (Copenh). 1992;127(3):193–9. [PubMed: 1414142]

284.

Ogura M, Kusaka I, Nagasaka S, Yatagai T, Shinozaki S, Itabashi N, et al. Unilateral adrenalectomy improves insulin resistance and diabetes mellitus in a patient with ACTH-independent macronodular adrenal hyperplasia. Endocr J. 2003;50(6):715–21. [PubMed: 14709842]

285.

Lamas C, Alfaro JJ, Lucas T, Lecumberri B, Barcelo B, Estrada J. Is unilateral adrenalectomy an alternative treatment for ACTH-independent macronodular adrenal hyperplasia?: Long-term follow-up of four cases. Eur J Endocrinol. 2002;146(2):237–40. [PubMed: 11834434]

286.

Lacroix A, Hamet P, Boutin JM. Leuprolide acetate therapy in luteinizing hormone--dependent Cushing's syndrome. N Engl J Med. 1999;341(21):1577–81. [PubMed: 10564687]

287.

Lacroix A, Tremblay J, Rousseau G, Bouvier M, Hamet P. Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing's syndrome. N Engl J Med. 1997;337(20):1429–34. [PubMed: 9358140]

288.

Valimaki M, Pelkonen R, Porkka L, Sivula A, Kahri A. Long-term results of adrenal surgery in patients with Cushing's syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf). 1984;20(2):229–36. [PubMed: 6325048]

289.

Sarkar R, Thompson NW, McLeod MK. The role of adrenalectomy in Cushing's syndrome. Surgery. 1990;108(6):1079–84. [PubMed: 2247833]

290.

McCallum RW, Connell JM. Laparoscopic adrenalectomy. Clin Endocrinol (Oxf). 2001;55(4):435–6. [PubMed: 11678823]

291.

Elfenbein DM, Scarborough JE, Speicher PJ, Scheri RP. Comparison of laparoscopic versus open adrenalectomy: results from American College of Surgeons-National Surgery Quality Improvement Project. J Surg Res. 2013;184(1):216–20. [PubMed: 23664532]

292.

Raffaelli M, Brunaud L, De Crea C, Hoche G, Oragano L, Bresler L, et al. Synchronous bilateral adrenalectomy for Cushing's syndrome: laparoscopic versus posterior retroperitoneoscopic versus robotic approach. World J Surg. 2014;38(3):709–15. [PubMed: 24240671]

293.

Taffurelli G, Ricci C, Casadei R, Selva S, Minni F. Open adrenalectomy in the era of laparoscopic surgery: a review. Updates Surg. 2017;69(2):135–43. [PubMed: 28540670]

294.

Bellantone R, Ferrante A, Boscherini M, Lombardi CP, Crucitti P, Crucitti F, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997;122(6):1212–8. [PubMed: 9426440]

295.

Magee BJ, Gattamaneni HR, Pearson D. Adrenal cortical carcinoma: survival after radiotherapy. Clin Radiol. 1987;38(6):587–8. [PubMed: 3121234]

296.

de Castro F, Isa W, Aguera L, Rosell Costa D, Abad JI, Robles JE, et al. Actas Urol Esp. 1993;17(1):30–4. [Primary adrenal carcinoma] [PubMed: 8452080]

297.

Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91(11):4501–4. [PubMed: 16895957]

298.

Broersen LHA, Jha M, Biermasz NR, Pereira AM, Dekkers OM. Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis. Pituitary. 2018;21(6):631–41. [PMC free article: PMC6244780] [PubMed: 29855779]

299.

Carballeira A, Fishman LM, Jacobi JD. Dual sites of inhibition by metyrapone of human adrenal steroidogenesis: correlation of in vivo and in vitro studies. J Clin Endocrinol Metab. 1976;42(4):687–95. [PubMed: 1262443]

300.

Trainer PJ, Besser M. Cushing's syndrome. Therapy directed at the adrenal glands. Endocrinol Metab Clin North Am. 1994;23(3):571–84. [PubMed: 7805655]

301.

Owen LJ, Halsall DJ, Keevil BG. Cortisol measurement in patients receiving metyrapone therapy. Ann Clin Biochem. 2010;47(Pt 6):573–5. [PubMed: 20926474]

302.

Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf). 1991;35(2):169–78. [PubMed: 1657460]

303.

Aron DC, Schnall AM, Sheeler LR. Cushing's syndrome and pregnancy. Am J Obstet Gynecol. 1990;162(1):244–52. [PubMed: 2405679]

304.

Buescher MA, McClamrock HD, Adashi EY. Cushing syndrome in pregnancy. Obstet Gynecol. 1992;79(1):130–7. [PubMed: 1727571]

305.

Machado MC, Fragoso M, Bronstein MD. Pregnancy in Patients with Cushing's Syndrome. Endocrinol Metab Clin North Am. 2018;47(2):441–9. [PubMed: 29754643]

306.

Schteingart DE. Drugs in the medical treatment of Cushing's syndrome. Expert Opin Emerg Drugs. 2009;14(4):661–71. [PubMed: 19939210]

307.

Feelders RA, Hofland LJ, de Herder WW. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology. 2010;92 Suppl 1:111–5. [PubMed: 20829630]

308.

Connell JM, Cordiner J, Davies DL, Fraser R, Frier BM, McPherson SG. Pregnancy complicated by Cushing's syndrome: potential hazard of metyrapone therapy. Case report. Br J Obstet Gynaecol. 1985;92(11):1192–5. [PubMed: 4063238]

309.

Santen RJ, Van den Bossche H, Symoens J, Brugmans J, DeCoster R. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab. 1983;57(4):732–6. [PubMed: 6309882]

310.

Pont A, Goldman ES, Sugar AM, Siiteri PK, Stevens DA. Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia. Arch Intern Med. 1985;145(8):1429–31. [PubMed: 4040740]

311.

Engelhardt D, Dorr G, Jaspers C, Knorr D. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase. Klin Wochenschr. 1985;63(13):607–12. [PubMed: 2993735]

312.

Engelhardt D, Weber MM, Miksch T, Abedinpour F, Jaspers C. The influence of ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices. Clin Endocrinol (Oxf). 1991;35(2):163–8. [PubMed: 1934533]

313.

Steen RE, Kapelrud H, Haug E, Frey H. In vivo and in vitro inhibition by ketoconazole of ACTH secretion from a human thymic carcinoid tumour. Acta Endocrinol (Copenh). 1991;125(3):331–4. [PubMed: 1659100]

314.

Chou SC, Lin JD. Long-term effects of ketoconazole in the treatment of residual or recurrent Cushing's disease. Endocr J. 2000;47(4):401–6. [PubMed: 11075720]

315.

Ahmed M, Kanaan I, Alarifi A, Ba-Essa E, Saleem M, Tulbah A, et al. ACTH-producing pituitary cancer: experience at the King Faisal Specialist Hospital & Research Centre. Pituitary. 2000;3(2):105–12. [PubMed: 11141693]

316.

Amado JA, Pesquera C, Gonzalez EM, Otero M, Freijanes J, Alvarez A. Successful treatment with ketoconazole of Cushing's syndrome in pregnancy. Postgrad Med J. 1990;66(773):221–3. [PMC free article: PMC2429473] [PubMed: 2362890]

317.

Berwaerts J, Verhelst J, Mahler C, Abs R. Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol. 1999;13(3):175–82. [PubMed: 10451809]

318.

McCance DR, Hadden DR, Kennedy L, Sheridan B, Atkinson AB. Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. Clin Endocrinol (Oxf). 1987;27(5):593–9. [PubMed: 3450457]

319.

Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, et al. Ketoconazole in Cushing's disease: is it worth a try? J Clin Endocrinol Metab. 2014;99(5):1623–30. [PubMed: 24471573]

320.

Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology. 1984;86(3):503–13. [PubMed: 6319220]

321.

McCance DR, Ritchie CM, Sheridan B, Atkinson AB. Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet. 1987;1(8532):573. [PubMed: 2881126]

322.

Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf). 1991;35(4):347–52. [PubMed: 1752063]

323.

Tucker WS Jr, Snell BB, Island DP, Gregg CR. Reversible adrenal insufficiency induced by ketoconazole. JAMA. 1985;253(16):2413–4. [PubMed: 3981770]

324.

Miettinen TA. Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res. 1988;29(1):43–51. [PubMed: 3356951]

325.

Schwetz V, Aberer F, Stiegler C. T RP, Obermayer-Pietsch B, Pilz S. Fluconazole and acetazolamide in the treatment of ectopic Cushing's syndrome with severe metabolic alkalosis. Endocrinol Diabetes Metab Case Rep. 2015;2015:150027. [PMC free article: PMC4570129] [PubMed: 26380091]

326.

Canteros TM, De Miguel V, Fainstein-Day P. Fluconazole treatment in severe ectopic Cushing syndrome. Endocrinol Diabetes Metab Case Rep. 2019;2019(1) [PMC free article: PMC6612060] [PubMed: 31373475]

327.

van der Pas R, Hofland LJ, Hofland J, Taylor AE, Arlt W, Steenbergen J, et al. Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol. 2012;215(3):403–12. [PubMed: 23038793]

328.

Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet. 1983;1(8336):1270. [PubMed: 6134053]

329.

Weber MM, Lang J, Abedinpour F, Zeilberger K, Adelmann B, Engelhardt D. Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis. Clin Investig. 1993;71(11):933–8. [PubMed: 8312688]

330.

Lamberts SW, Bons EG, Bruining HA, de Jong FH. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther. 1987;240(1):259–64. [PubMed: 3027305]

331.

De Coster R, Beerens D, Haelterman C, Wouters L. Effects of etomidate on cortisol biosynthesis in isolated guinea-pig adrenal cells: comparison with metyrapone. J Endocrinol Invest. 1985;8(3):199–202. [PubMed: 2993407]

332.

Allolio B, Schulte HM, Kaulen D, Reincke M, Jaursch-Hancke C, Winkelmann W. Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin Wochenschr. 1988;66(8):361–4. [PubMed: 3392892]

333.

Herrmann BL, Mitchell A, Saller B, Stolke D, Forsting M, Frilling A, et al. Dtsch Med Wochenschr. 2001;126(9):232–4. [Transsphenoidal hypophysectomy of a patient with an ACTH-producing pituitary adenoma and an "empty sella" after pretreatment with etomidate] [PubMed: 11256037]

334.

Drake WM, Perry LA, Hinds CJ, Lowe DG, Reznek RH, Besser GM. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. J Clin Endocrinol Metab. 1998;83(10):3542–4. [PubMed: 9768661]

335.

Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J Clin Endocrinol Metab. 2001;86(9):4104–8. [PubMed: 11549633]

336.

Greening JE, Brain CE, Perry LA, Mushtaq I, Sales Marques J, Grossman AB, et al. Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease. Horm Res. 2005;64(3):140–3. [PubMed: 16192738]

337.

Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab. 1990;70(5):1426–30. [PubMed: 2159485]

338.

Preda VA, Sen J, Karavitaki N, Grossman AB. Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. Eur J Endocrinol. 2012;167(2):137–43. [PubMed: 22577107]

339.

Young RB, Bryson MJ, Sweat ML, Street JC. Complexing of DDT and o,p'DDD with adrenal cytochrome P-450 hydroxylating systems. J Steroid Biochem. 1973;4(6):585–91. [PubMed: 4789318]

340.

Cueto C, Brown JH, Richardson AP Jr. Biological studies on an adrenocorticolytic agent and the isolation of the active components. Endocrinology. 1958;62(3):334–9. [PubMed: 13512246]

341.

Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25(7):891–7. [PubMed: 11572030]

342.

Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372–80. [PubMed: 17554118]

343.

Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322(17):1195–201. [PubMed: 2325710]

344.

Schteingart DE, Tsao HS, Taylor CI, McKenzie A, Victoria R, Therrien BA. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med. 1980;92(5):613–9. [PubMed: 6247946]

345.

Leiba S, Weinstein R, Shindel B, Lapidot M, Stern E, Levavi H, et al. The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol (Paris). 1989;50(1):49–53. [PubMed: 2729882]

346.

Maher VM, Trainer PJ, Scoppola A, Anderson JV, Thompson GR, Besser GM. Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia. Q J Med. 1992;84(305):671–9. [PubMed: 1480741]

347.

Haak HR, Caekebeke-Peerlinck KM, van Seters AP, Briet E. Prolonged bleeding time due to mitotane therapy. Eur J Cancer. 1991;27(5):638–41. [PubMed: 1828976]

348.

Hogan TF, Citrin DL, Johnson BM, Nakamura S, Davis TE, Borden EC. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer. 1978;42(5):2177–81. [PubMed: 719602]

349.

Vilar O, Tullner WW. Effects of o,p' DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex. Endocrinology. 1959;65(1):80–6. [PubMed: 13663851]

350.

Lamberts SW, de Herder WW, Krenning EP, Reubi JC. A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome. J Clin Endocrinol Metab. 1994;78(1):17–9. [PubMed: 7904612]

351.

Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab. 2006;91(11):4482–8. [PubMed: 16940446]

352.

Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005;152(4):645–54. [PubMed: 15817922]

353.

Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115–22. [PubMed: 18957506]

354.

Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366(10):914–24. [PubMed: 22397653]

355.

Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, et al. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes Endocrinol. 2018;6(1):17–26. [PubMed: 29032078]

356.

Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med. 2010;362(19):1846–8. [PubMed: 20463350]

357.

Hayashi K, Inoshita N, Kawaguchi K, Ibrahim Ardisasmita A, Suzuki H, Fukuhara N, et al. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease. Eur J Endocrinol. 2016;174(2):213–26. [PubMed: 26578638]

358.

Pivonello R, Ferone D, de Herder WW, de Krijger RR, Waaijers M, Mooij DM, et al. Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J Clin Endocrinol Metab. 2004;89(9):4493–502. [PubMed: 15356054]

359.

Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol. 2010;163(5):709–16. [PubMed: 20702648]

360.

Trifiro G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, et al. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study. Drug Saf. 2012;35(2):159–71. [PubMed: 22204718]

361.

Curto L, Torre ML, Ferrau F, Pitini V, Altavilla G, Granata F, et al. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. ScientificWorldJournal. 2010;10:2132–8. [PMC free article: PMC5763678] [PubMed: 21057727]

362.

Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, et al. SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes. 2010;118(10):760–3. [PubMed: 20496311]

363.

McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf). 2009;71(2):226–33. [PubMed: 19067722]

364.

Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, et al. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 2008;115(2):261–2. [PubMed: 17926052]

365.

Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, et al. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab. 2010;95(11):E280–90. [PMC free article: PMC5393383] [PubMed: 20668043]

366.

Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010;95(10):4592–9. [PubMed: 20660056]

367.

Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest. 2001;108(8):1123–31. [PMC free article: PMC209498] [PubMed: 11602619]

368.

Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002;8(11):1281–7. [PubMed: 12379847]

369.

Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest. 2003;111(9):1381–8. [PMC free article: PMC154441] [PubMed: 12727930]

370.

Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol. 2004;151(2):173–8. [PubMed: 15296471]

371.

Cannavo S, Arosio M, Almoto B, Dall'Asta C, Ambrosi B. Effectiveness of long-term rosiglitazone administration in patients with Cushing's disease. Clin Endocrinol (Oxf). 2005;63(1):118–9. [PubMed: 15963072]

372.

Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab. 2005;90(3):1340–6. [PubMed: 15585550]

373.

Lacroix A, N'Diaye N, Mircescu H, Tremblay J, Hamet P. The diversity of abnormal hormone receptors in adrenal Cushing's syndrome allows novel pharmacological therapies. Braz J Med Biol Res. 2000;33(10):1201–9. [PubMed: 11004721]

374.

Preumont V, Mermejo LM, Damoiseaux P, Lacroix A, Maiter D. Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome. Horm Metab Res. 2011;43(4):287–91. [PubMed: 21264796]

375.

Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011;124(18):1945–55. [PubMed: 21986283]

376.

Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, et al. LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2014;99(4):1375–83. [PubMed: 24423285]

377.

Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, Shimizu C, et al. Osilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. Pituitary. 2016;19(2):138–48. [PMC free article: PMC4799251] [PubMed: 26542280]

378.

Fleseriu M, Pivonello R, Elenkova A, Salvatori R, Auchus RJ, Feelders RA, et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol. 2019;7(11):855–65. [PubMed: 31542384]

379.

Baulieu EE. The steroid hormone antagonist RU486. Mechanism at the cellular level and clinical applications. Endocrinol Metab Clin North Am. 1991;20(4):873–91. [PubMed: 1778181]

380.

Bertagna X, Basin C, Picard F, Varet B, Bertagna C, Hucher M, et al. Peripheral antiglucocorticoid action of RU 486 in man. Clin Endocrinol (Oxf). 1988;28(5):537–41. [PubMed: 3214945]

381.

Healy DL, Chrousos GP, Schulte HM, Gold PW, Hodgen GD. Increased adrenocorticotropin, cortisol, and arginine vasopressin secretion in primates after the antiglucocorticoid steroid RU 486: dose response relationships. J Clin Endocrinol Metab. 1985;60(1):1–4. [PubMed: 2981083]

382.

Bertagna X, Bertagna C, Laudat MH, Husson JM, Girard F, Luton JP. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab. 1986;63(3):639–43. [PubMed: 3734034]

383.

Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97(6):2039–49. [PubMed: 22466348]

384.

Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol. 2009;160(6):1003–10. [PubMed: 19289534]

385.

Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol. 2007;157(5):561–9. [PubMed: 17984235]

386.

Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab. 1985;61(3):536–40. [PubMed: 2991327]

387.

Trainer PJ, Eastment C, Grossman AB, Wheeler MJ, Perry L, Besser GM. The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing's syndrome. Clin Endocrinol (Oxf). 1993;39(4):441–3. [PubMed: 8287570]

388.

van Seters AP, Moolenaar AJ. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol (Copenh). 1991;124(5):526–33. [PubMed: 1903011]

389.

Alexandraki KI, Kaltsas GA, le Roux CW, Fassnacht M, Ajodha S, Christ-Crain M, et al. Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clin Endocrinol (Oxf). 2010;72(3):305–11. [PubMed: 19473175]

390.

Workman RJ, Vaughn WK, Stone WJ. Dexamethasone suppression testing in chronic renal failure: pharmacokinetics of dexamethasone and demonstration of a normal hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab. 1986;63(3):741–6. [PubMed: 3734041]

391.

Nolan GE, Smith JB, Chavre VJ, Jubiz W. Spurious overestimation of plasma cortisol in patients with chronic renal failure. J Clin Endocrinol Metab. 1981;52(6):1242–5. [PubMed: 7229002]

392.

Luger A, Lang I, Kovarik J, Stummvoll HK, Templ H. Abnormalities in the hypothalamic-pituitary-adrenocortical axis in patients with chronic renal failure. Am J Kidney Dis. 1987;9(1):51–4. [PubMed: 3028134]

393.

Chan KC, Lit LC, Law EL, Tai MH, Yung CU, Chan MH, et al. Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment. Clin Chem. 2004;50(4):757–9. [PubMed: 15044334]

394.

Siamopoulos KC, Dardamanis M, Kyriaki D, Pappas M, Sferopoulos G, Alevisou V. Pituitary adrenal responsiveness to corticotropin-releasing hormone in chronic uremic patients. Perit Dial Int. 1990;10(2):153–6. [PubMed: 1964805]

395.

Ramirez G, Gomez-Sanchez C, Meikle WA, Jubiz W. Evaluation of the hypothalamic hypophyseal adrenal axis in patients receiving long-term hemodialysis. Arch Intern Med. 1982;142(8):1448–52. [PubMed: 6285845]

396.

Calao AM. Pituitary adenomas in childhood. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000.

397.

Weber A, Trainer PJ, Grossman AB, Afshar F, Medbak S, Perry LA, et al. Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome. Clin Endocrinol (Oxf). 1995;43(1):19–28. [PubMed: 7641408]

398.

Lee PD, Winter RJ, Green OC. Virilizing adrenocortical tumors in childhood: eight cases and a review of the literature. Pediatrics. 1985;76(3):437–44. [PubMed: 3162151]

399.

Savage MO, Lienhardt A, Lebrethon MC, Johnston LB, Huebner A, Grossman AB, et al. Cushing's disease in childhood: presentation, investigation, treatment and long-term outcome. Horm Res. 2001;55 Suppl 1:24–30. [PubMed: 11408758]

400.

Urbanic RC, George JM. Cushing's disease--18 years' experience. Medicine (Baltimore). 1981;60(1):14–24. [PubMed: 7453562]

401.

Streeten DH, Faas FH, Elders MJ, Dalakos TG, Voorhess M. Hypercortisolism in childhood: shortcomings of conventional diagnostic criteria. Pediatrics. 1975;56(5):797–803. [PubMed: 1196738]

402.

Martinelli CE Jr, Sader SL, Oliveira EB, Daneluzzi JC, Moreira AC. Salivary cortisol for screening of Cushing's syndrome in children. Clin Endocrinol (Oxf). 1999;51(1):67–71. [PubMed: 10468967]

403.

Gafni RI, Papanicolaou DA, Nieman LK. Nighttime salivary cortisol measurement as a simple, noninvasive, outpatient screening test for Cushing's syndrome in children and adolescents. J Pediatr. 2000;137(1):30–5. [PubMed: 10891818]

404.

Batista DL, Riar J, Keil M, Stratakis CA. Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics. 2007;120(3):e575–86. [PubMed: 17698579]

405.

Carpenter PC. Diagnostic evaluation of Cushing's syndrome. Endocrinol Metab Clin North Am. 1988;17(3):445–72. [PubMed: 3065076]

406.

Magiakou MA, Mastorakos G, Oldfield EH, Gomez MT, Doppman JL, Cutler GB Jr, et al. Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med. 1994;331(10):629–36. [PubMed: 8052272]

407.

Dias R, Storr HL, Perry LA, Isidori AM, Grossman AB, Savage MO. The discriminatory value of the low-dose dexamethasone suppression test in the investigation of paediatric Cushing's syndrome. Horm Res. 2006;65(3):159–62. [PubMed: 16514243]

408.

Hanson JA, Weber A, Reznek RH, Cotterill AM, Ross RJ, Harris RJ, et al. Magnetic resonance imaging of adrenocortical adenomas in childhood: correlation with computed tomography and ultrasound. Pediatr Radiol. 1996;26(11):794–9. [PubMed: 8929380]

409.

Storr HL, Afshar F, Matson M, Sabin I, Davies KM, Evanson J, et al. Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing's disease. Eur J Endocrinol. 2005;152(6):825–33. [PubMed: 15941921]

410.

Storr HL, Plowman PN, Carroll PV, Francois I, Krassas GE, Afshar F, et al. Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing's disease: an effective second-line treatment. J Clin Endocrinol Metab. 2003;88(1):34–7. [PubMed: 12519825]

411.

Davies JH, Storr HL, Davies K, Monson JP, Besser GM, Afshar F, et al. Final adult height and body mass index after cure of paediatric Cushing's disease. Clin Endocrinol (Oxf). 2005;62(4):466–72. [PubMed: 15807878]

412.

Nana M, Williamson C. Pituitary and Adrenal Disorders of Pregnancy. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000. [PubMed: 25905272]

413.

Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK. Cushing's syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab. 2005;90(5):3077–83. [PubMed: 15705919]

414.

Carr BR, Parker CR Jr, Madden JD, MacDonald PC, Porter JC. Maternal plasma adrenocorticotropin and cortisol relationships throughout human pregnancy. Am J Obstet Gynecol. 1981;139(4):416–22. [PubMed: 6258436]

415.

Ambroziak U, Kondracka A, Bartoszewicz Z, Krasnodebska-Kiljanska M, Bednarczuk T. The morning and late-night salivary cortisol ranges for healthy women may be used in pregnancy. Clin Endocrinol (Oxf). 2015;83(6):774–8. [PubMed: 26173372]

416.

Lopes LM, Francisco RP, Galletta MA, Bronstein MD. Determination of nighttime salivary cortisol during pregnancy: comparison with values in non-pregnancy and Cushing's disease. Pituitary. 2016;19(1):30–8. [PubMed: 26346684]

417.

Barasch E, Sztern M, Spinrad S, Chayen R, Servadio C, Kaufman H, et al. Pregnancy and Cushing's syndrome: example of endocrine interaction. Isr J Med Sci. 1988;24(2):101–4. [PubMed: 3281917]

418.

Ross RJ, Chew SL, Perry L, Erskine K, Medbak S, Afshar F. Diagnosis and selective cure of Cushing's disease during pregnancy by transsphenoidal surgery. Eur J Endocrinol. 1995;132(6):722–6. [PubMed: 7788013]

419.

Bronstein MD, Machado MC, Fragoso MC. MANAGEMENT OF ENDOCRINE DISEASE: Management of pregnant patients with Cushing's syndrome. Eur J Endocrinol. 2015;173(2):R85–91. [PubMed: 25872515]

420.

Caimari F, Valassi E, Garbayo P, Steffensen C, Santos A, Corcoy R, et al. Cushing's syndrome and pregnancy outcomes: a systematic review of published cases. Endocrine. 2017;55(2):555–63. [PubMed: 27704478]

421.

Plotz CM, Knowlton AI, Ragan C. Natural course of Cushing's syndrome as compared with the course of rheumatoid arthritis treated by hormones. Ann Rheum Dis. 1952;11(4):308–9. [PubMed: 13017491]

422.

Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E, et al. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab. 2009;94(8):2743–50. [PubMed: 19454584]

423.

Clayton RN, Jones PW, Reulen RC, Stewart PM, Hassan-Smith ZK, Ntali G, et al. Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol. 2016;4(7):569–76. [PubMed: 27265184]

424.

Alexandraki KI, Kaltsas GA, Isidori AM, Storr HL, Afshar F, Sabin I, et al. Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study. Eur J Endocrinol. 2013;168(4):639–48. [PubMed: 23371975]

425.

Swearingen B, Biller BM, Barker FG 2nd, Katznelson L, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med. 1999;130(10):821–4. [PubMed: 10366371]

426.

Valassi E, Tabarin A, Brue T, Feelders RA, Reincke M, Netea-Maier R, et al. High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. Eur J Endocrinol. 2019;181(5):461–72. [PubMed: 31480014]

427.

Savage MO, Storr HL, Chan LF, Grossman AB. Diagnosis and treatment of pediatric Cushing's disease. Pituitary. 2007;10(4):365–71. [PubMed: 17570065]

428.

Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK. Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab. 2006;91(2):447–53. [PubMed: 16278266]

429.

Santos A, Resmini E, Martinez Momblan MA, Valassi E, Martel L, Webb SM. Quality of Life in Patients With Cushing's Disease. Front Endocrinol (Lausanne). 2019;10:862. [PMC free article: PMC6917662] [PubMed: 31920973]

430.

Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP. The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab. 1997;82(3):912–9. [PubMed: 9062506]

431.

Forget H, Lacroix A, Cohen H. Persistent cognitive impairment following surgical treatment of Cushing's syndrome. Psychoneuroendocrinology. 2002;27(3):367–83. [PubMed: 11818172]

432.

Manning PJ, Evans MC, Reid IR. Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol (Oxf). 1992;36(3):229–34. [PubMed: 1563076]

433.

Di Somma C, Pivonello R, Loche S, Faggiano A, Klain M, Salvatore M, et al. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol (Oxf). 2003;58(3):302–8. [PubMed: 12608935]

434.

Di Somma C, Colao A, Pivonello R, Klain M, Faggiano A, Tripodi FS, et al. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clin Endocrinol (Oxf). 1998;48(5):655–62. [PubMed: 9666879]

435.

Hermus AR, Smals AG, Swinkels LM, Huysmans DA, Pieters GF, Sweep CF, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab. 1995;80(10):2859–65. [PubMed: 7559865]

436.

Dimopoulos MA, Fernandez JF, Samaan NA, Holoye PY, Vassilopoulou-Sellin R. Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer. 1992;69(1):66–71. [PubMed: 1309310]